Uncovering the role of microRNA-206 in Duchenne muscular dystrophy by Bulaklak, Karen
 
 
 
 
 
UNCOVERING THE ROLE OF MICRORNA-206 IN DUCHENNE MUSCULAR 
DYSTROPHY 
 
 
 
 
 
Karen Jennifer Bulaklak 
 
 
 
 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Pharmaceutical Sciences in the Eshelman School of Pharmacy. 
 
 
 
 
 
Chapel Hill 
2017 
 
 
 
 
 
Approved by: 
Xiao Xiao 
Leaf Huang 
Shawn Hingtgen 
Joan Taylor 
Charles Gersbach 
  
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 
Karen Jennifer Bulaklak 
ALL RIGHTS RESERVED 
 
 iii 
 
ABSTRACT 
Karen Jennifer Bulaklak: Uncovering the role of microRNA-206 in Duchenne muscular 
dystrophy 
(Under the direction of Xiao Xiao) 
 
Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder for 
which there is no cure. It is caused by a defect in the dystrophin gene, which encodes 
an important structural and regulatory protein at the muscle membrane. In DMD, the 
absence of dystrophin protein renders the muscle fragile and susceptible to damage. 
Patients gradually lose muscle mass and die prematurely from cardiac or respiratory 
complications. Current treatments are palliative and do not address the underlying 
cause. 
Gene therapies that replace or correct mutated genes have shown promise for 
DMD. Recombinant adeno-associated viruses (rAAVs) are popular gene delivery 
vehicles because of their non-pathogenic nature and ability to establish long-term and 
efficient gene transfer. Still, restoring dystrophin is challenging and cannot completely 
alleviate motor deficits. While DMD is caused by a single gene defect, many secondary 
disease mechanisms are involved, such as ischemia and fibrosis. Thus, a strategy 
addressing multiple pathological mechanisms may be beneficial. 
MicroRNAs (miRs) are small, regulatory RNA molecules that inhibit target gene 
expression. A skeletal muscle-restricted microRNA, miR-206, is highly upregulated in 
dystrophic muscle. Although its role in DMD is unclear, several miR-206 targets have 
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shown benefit for DMD, including vascular endothelial growth factor A (VEGFA) and 
utrophin. Counteracting miR-206 thus presents a viable treatment for DMD.  
The goal of this study was to determine if downregulation of miR-206 would 
increase therapeutic gene expression, inhibiting secondary disease mechanisms and 
improving dystrophic symptoms. I demonstrated that a rAAV carrying antisense 
sequences against miR-206, AAV-anti-miR-206, can ameliorate motor deficits in 
dystrophic mdx mice. To understand its therapeutic mechanism, I focused on two 
prominent disease pathways. 
Functional ischemia is a major contributor to the dystrophic phenotype and 
exacerbates muscle damage. Decreasing miR-206 appears to increase proangiogenic 
VEGFA expression, improving vascularization in mdx muscle. Also, overexpression of 
utrophin, a dystrophin paralog, can improve membrane stability and impede DMD 
progression. I observed increased utrophin in mdx muscle with miR-206 reduction, 
along with improved pathology, reduced fibrosis and delayed disease progression. 
Altogether, this study characterizes a novel therapeutic strategy for DMD and 
sheds light on a contributing factor in secondary pathology.  
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CHAPTER 1: INTRODUCTION 
 
I. Muscular dystrophy 
 The muscular dystrophies (MDs) are a heterogenous group of rare genetic 
diseases characterized by progressive skeletal muscle degeneration and weakness. 
The MDs vary greatly in age of disease onset, severity, inheritance pattern, as well as 
muscle groups affected (Dalkilic and Kunkel 2003, Wallace and McNally 2009). Over 30 
types of muscular dystrophy have been identified to date, which are classified into 
several major groups according to predominant distribution of symptoms (summarized 
in Table 1). These include: Duchenne and Becker MD, Emery-Dreifuss MD, congenital 
MD, limb girdle MD, facioscapulohumeral MD, distal MD and oculopharyngeal MD 
(Emery 2002). Despite sharing similar patterns of muscle weakness, MDs within each 
group can vary drastically in both clinical presentation and genetic etiology. For 
example, limb girdle muscular dystrophy can be further subdivided into 15 unique 
diseases (Guglieri, Straub et al. 2008). While the symptoms and causative genes for 
many MDs are known, current treatments are palliative and cannot prevent further 
muscle deterioration (Emery 2002).  
Muscular dystrophies have been linked to mutations in 29 distinct genetic loci 
(Dalkilic and Kunkel 2003, Wallace and McNally 2009). These mutations lead to the loss 
of function in genes encoding components of individual muscle cells, or myofibers, such 
as the membrane (sarcolemma), cytoskeleton, extracellular matrix and nuclear 
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membrane. Defects in gene products involved in muscle membrane repair, such as 
dysferlin, have also been found (Cohn 2000, Dalkilic and Kunkel 2003, Wallace and 
McNally 2009). The majority of these genes encode constituents of the dystrophin-
associated protein complex (DAPC), which spans across the sarcolemma and serves 
as a critical linkage between the extracellular matrix (ECM) and cytoskeletal actin 
fllaments (F-actin) that mediate movement (Figure 1). The DAPC provides mechanical 
stability to the sarcolemma by anchoring the cytoskeleton to the ECM as well as 
transmitting contractile force to the basement membrane to minimize stress on the lipid 
bilayer (Campbell and Stull 2003, Wallace and McNally 2009). Several proteins also 
participate in signaling cascades important for muscle development and maintenance 
(Jarmin, Kymalainen et al. 2014). The proteins within the DAPC can be classified into 3 
distinct subcomplexes: the cytoskeletal proteins (dystrophin, syntrophins, α-
dystrobrevin), sarcolemmal proteins (dystroglycan α and β subunits) and the 
sarcoglycans (α, β, γ and δ subunits) and sarcospan (Cohn 2000). The absence of any 
of these components renders the membrane fragile and susceptible to contraction-
induced damage, eventually leading to muscle degeneration (Wallace and McNally 
2009). 
II. Molecular pathogenesis of DMD 
Global muscle degeneration begins with myofiber necrosis caused by membrane 
permeability. Reduced membrane integrity results in high serum levels of muscle 
cytoplasm (sarcoplasm)-restricted enzymes, such as creatine kinase (Chargé and 
Rudnicki 2004). Membrane permeability and disorganization of structural components of 
the myofiber allow an unregulated influx of Ca2+ into the sarcoplasm, yet the mechanism 
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by which this occurs is not well-known. This event activates degenerative and well as 
reparative processes. Calcium-dependent proteases, such as calpains, degrade 
myofibrillar and cytoskeletal proteins, such as myosin, α-actinin, talin and vinculin. In 
addition, calpains can proteolytically cleave and thus activate other proteolytic enzymes, 
exacerbating injury. Raised intracellular calcium levels also stimulate dysferlin-mediated 
membrane repair; however, it cannot compensate for advanced muscle damage (Tidball 
1995, Wallace and McNally 2009). The injured myofiber releases factors that activate 
and recruit resident and circulating inflammatory cells, predominantly neutrophils and 
macrophages. Following initial neutrophil infiltration (~1 to 6 hours post-injury), 
macrophages become more abundant (~48 hours later). These cells play complex roles 
in both promoting damage by releasing cytolytic factors and recruiting myogenic cells to 
initiate muscle repair (Chargé and Rudnicki 2004, Tidball 2005). 
Following injury, myofibers release mitogens, such as hepatocyte growth factor 
(HGF), which activate muscle stem cells called satellite cells. Satellite cells are normally 
quiescent and reside in the basement membrane of the muscle. Once activated, 
satellite cells proliferate and are chemotactically drawn to the site of injury, where they 
produce muscle precursor cells, or myoblasts. Myoblasts then commit to the myogenic 
lineage, which is marked by myf5 and MyoD expression. Proliferating myoblasts 
continue to differentiate and fuse to existing fibers at the site of injury. In muscular 
dystrophy, normal regeneration may be impeded by defective muscle precursors, 
improper fusion or an unfavorable microenvironment (Wozniak, Kong et al. 2005, 
Wallace and McNally 2009). “Replicative aging,” which is defined as the premature 
senescence of muscle precursors, may also prevent regeneration due to telomere 
 4 
shortening from constant proliferation (Wozniak, Kong et al. 2005, Wallace and McNally 
2009). 
In addition to muscle precursors, resident fibroblasts are stimulated in response 
to injury. Activated fibroblasts synthesize growth factors and extracellular matrix (ECM) 
components, including fibronectin, collagen I and III and proteoglycan, in order to 
promote cellular proliferation and provide a scaffold for infiltrating cells. Although 
fibroblast activity assists in proper regeneration in normal muscle, continuous damage 
and inflammation that are observed in muscular dystrophy results in permanent fibrotic 
deposition, ultimately replacing functional muscle (Serrano and Muñoz-Cánoves 2010). 
Satellite cells extracted from dystrophic mice have also been shown to overproduce 
collagen I and III (Alexakis, Partridge et al. 2007). Additionally, ECM components can 
sequester factors, such as insulin-like growth factor-1 (IGF-1), which are necessary for 
myoblast proliferation (Wallace and McNally 2009).  
In summary, the dystrophic phenotype is marked by continuous muscle 
degeneration, usually initiated by genetic defects that impair the membrane, and the 
concurrent cellular processes, including inflammation, regeneration and fibrosis, which 
work to repair and exacerbate myofiber damage. 
III. Duchenne muscular dystrophy 
 Originally described in 1851, Duchenne muscular dystrophy (DMD) is the most 
well-studied and common form of muscular dystrophy (~30% of MD cases), which 
affects about 1 in 3,500 male live births (Nonaka 1998). DMD is a sex-linked inherited 
muscle disorder that commonly affects young boys. The disease is characterized by 
progressive and debilitating weakness due to widespread degeneration in proximal 
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muscle (close to torso). Disease onset occurs in early childhood (~2 to 5 years of age) 
and initial symptoms include difficulties with walking, running and climbing stairs 
(Willmann, Possekel et al. 2009). About 20% of DMD patients also have some degree 
of mental impairment. Patients usually lose the ability to walk (non-ambulatory) in their 
early teens and cardiac and respiratory muscle failure are often observed in their late 
teens or early 20s. Presently available treatments, such as corticosteroid therapy, 
assisted ventilation and tracheostomy, have prolonged the lifespan of DMD patients. 
However, most eventually succumb to premature death in their 30s or 40s from 
pneumonia coupled with respiratory or cardiac insufficiency (Moser 1984, Emery 2002, 
Khurana and Davies 2003, Jarmin, Kymalainen et al. 2014). Becker muscular dystrophy 
(BMD) is a milder form of DMD that displays similar muscle distribution, but exhibits less 
severe symptoms and a slower rate of progression. Disease onset occurs later in life 
(~12 years of age) and patients survive well into their 40s and 50s (Blake, Weir et al. 
2002, Emery 2002).  
Duchenne and Becker muscular dystrophy are caused by mutations of the 
dystrophin gene, which encodes the 427 kDa dystrophin protein. In DMD, dystrophin is 
completely absent or greatly reduced in skeletal and cardiac muscle, while a truncated 
and partially functional dystrophin is present in BMD (Cohn 2000). Dystrophin was the 
first protein linked to muscular dystrophy pathogenesis and the recognition of its key 
role in muscle membrane integrity led to elucidation of other dystrophin-associated 
protein complex components. The full-length dystrophin protein can be organized into 
four major regions based on protein binding and sequence homology: the NH2 terminal 
domain, central rod domain, cysteine-rich domain and the COOH terminal domain. At its 
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NH2 terminus, dystrophin binds to cytoskeletal F-actin. The central rod domain contains 
24 spectrin-like repeats interspaced by four proline-rich hinge regions that confer 
flexibility to the protein. Immediately following the central rod domain is the WW domain, 
which interacts with the dystroglycan and sarcoglycan DAPC subcomplex through 
binding β-dystroglycan. The cysteine-rich region is thought to bind intracellular cations 
(Ca2+ and Zn2+) as well as calmodulin, a calcium-binding messenger protein that 
participates in calcium-dependent signal transduction. At its COOH terminus, dystrophin 
interacts with the cytoplasmic subcomplex of the DAPC by binding syntrophins and α-
dystrobrevin (Blake, Weir et al. 2002). Due to its close interactions with these 
subcomplexes, the presence of dystrophin is essential for assembly of the entire DAPC. 
In muscle biopsies from dystrophic humans and mice, sarcolemmal localization of 
syntrophin β1, α-sarcoglycan, δ-sarcoglycan, α-dystroglycan and β-dystroglycan were 
dramatically reduced. Genetic defects in other sarcolemmal proteins, as in the case of 
certain limb girdle MDs and congenital MDs, did not affect normal distribution of other 
DAPC constituents (Ohlendieck and Campbell 1991, Ohlendieck, Matsumura et al. 
1993). The loss of dystrophin also results in displacement of neuronal nitric oxide 
synthase (nNOS), which participates in signal transduction, at the sarcolemma 
(Wehling, Spencer et al. 2001, Kobayashi, Rader et al. 2008). Thus, the widespread 
and devastating muscle degeneration associated with DMD can be attributed to 
mutation of a single gene. 
As previously stated, Duchenne muscular dystrophy is a recessive X-linked 
disorder, predominantly affecting males. The dystrophin gene can be mapped to the 
p21 locus on the X chromosome (Xp21). The gene is 2.5 Mbp in length and contains 79 
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exons, encoding a 14 kb transcript. Most mutations found in DMD patients are gross 
intragenic deletions of the dystrophin gene (~65% of cases). These deletions commonly 
occur in two “hotspots” that encompass exons 45 through 53 and exons 2 through 20. 
These regions encode part of the rod domain and actin-binding site along with part of 
the rod domain, respectively. About one-third of cases are due to small deletions or 
point mutations that result in non-sense or frame shift mutations, introducing a 
premature stop codon. The remaining cases of DMD result from duplications (1 to 5%), 
or intronic deletions (Blake, Weir et al. 2002, Muntoni, Torelli et al. 2003). No direct 
correlation between the size of the deletion and disease severity has been found. For 
example, missense mutations in the NH2 terminal or cysteine-rich domain resulted in 
severe DMD phenotypes, while deletion of a large portion of the central rod domain 
(~46% of the dystrophin coding sequence) resulted in a mild case of BMD. As long as 
the normal open reading frame (ORF) is maintained, mutations in the dystrophin gene 
can be tolerated and in the case of BMD, produce a shorter, yet functional, protein. 
IV. Animal models of DMD 
Animal models of DMD have been used extensively to better understand disease 
pathology and develop new therapies. The most commonly used model is the 
dystrophin-deficient mdx mouse. The mdx mouse was first discovered in 1981 as a 
spontaneous mutant from a colony of C57BL/10 mice. These mice have a point 
mutation in exon 23 of the dystrophin gene that introduces a premature stop codon, 
which is found in about one-third of DMD patients. Unlike DMD patients who experience 
continuous muscle degeneration, mdx muscle pathology occurs in waves. An initial 
crisis of acute degeneration and regeneration is observed at 2 to 4 weeks, which is 
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marked by myofiber necrosis, centralized nuclei (actively regenerating fibers), variable 
myofiber sizes and elevated serum CK levels. By 8 weeks, muscle pathology returns to 
a chronic low level and fibrosis is not prominent in the hindlimb (Nonaka 1998, Grounds, 
Radley et al. 2008, Willmann, Possekel et al. 2009). In contrast, dystrophic pathology in 
the mdx diaphragm is severe and resembles the progressive degeneration, fibrosis and 
functional impairment found in DMD. By 6 months, a large number of diaphragm 
myofibers are necrotic and vary greatly in size. Also, the amount of connective tissue 
found in the mdx diaphragm is about 7 times greater than wild-type muscle and 10 
times greater than the mdx hindlimb (Stedman, Sweeney et al. 1991). Overall, motor 
function deficits found in mdx mice are not as pronounced in those found in humans. 
Reduction in relative forelimb strength by ~50% has been observed at 4 months of age. 
Forced exercise regimes involving eccentric contraction, such as wheel running or 
treadmill running, have been utilized to aggravate dystrophic symptoms for better 
comparison of DMD treatments (Grounds, Radley et al. 2008). Finally, no respiratory or 
cardiac deficiencies are observed until later in life (6 and 16 months, respectively) and 
lifespan is only slightly shorter than wild-type mice (Willmann, Possekel et al. 2009).  
Because of the milder phenotype of mdx mice, dystrophic murine models based 
on mdx have been generated by chemical and genetic manipulation informed by our 
understanding of dystrophin mutations present in DMD. For example, mdx52 mice were 
created by disruption of exon 52 and have large deletions in the dystrophin gene, yet 
are histologically similar to mdx mice. Double knockout models have also been created 
to recapitulate muscle membrane fragility and exacerbate mdx pathology (Willmann, 
Possekel et al. 2009). Dystrophin/α-dystrobrevin (mdx; adbn-/-) and dystrophin/α7 
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integrin (mdx; α7 integrin-/-) are both examples of mdx mice lacking important structural 
membrane proteins. Another commonly used model is the dystrophin/utrophin double 
knockout (mdx; utrophin-/-), which additionally lacks utrophin, an autosomal dystrophin 
paralog (Deconinck, Rafael et al. 1997). Compared to mdx, double knockout mice are 
extremely weak and skeletal and cardiac muscle display extensive necrosis and 
fibrosis. In addition, growth is stunted and spinal curvature (kyphosis) is observed. 
These mice also have a significantly lower body mass and dramatically reduced lifespan 
of 4 to 20 weeks (Deconinck, Rafael et al. 1997, Willmann, Possekel et al. 2009). 
Dystrophin mutations have been identified in many dog breeds, including 
Rottweilers, Pembroke Welsh corgis, Labrador retrievers and most notably golden 
retrievers (Kornegay, Bogan Jr Fau - Bogan et al. , Nonaka 1998, Willmann, Possekel 
et al. 2009). The dystrophin-deficient golden retriever model (GRMD) is the most 
studied canine model. GRMD dogs possess a point mutation at the 3’ splice site of 
intron 6, resulting in deletion of exon 7 and a frameshift in exon 8 (Nonaka 1998, 
Willmann, Possekel et al. 2009). Skeletal muscle lesions and cardiac pathology are 
more severe, which bears resemblance to DMD patients. In addition, GRMD dogs 
exhibit decreased respiratory capacity and motor function deficits, such as an 
uncoordinated, stiff gait and overall weakness. Death is usually caused by heart failure. 
Because of their similarities to human pathology, GRMD dogs have been extremely 
useful for evaluating potential therapies for muscular dystrophy (Khurana and Davies 
2003, Willmann, Possekel et al. 2009). 
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V. Gene therapies for DMD 
 Gene therapy involves the use of nucleic acids (DNA or RNA-based) to improve 
cellular function. Gene-based strategies have successfully treated a plethora of 
diseases, including spinal muscular atrophy, hereditary blindness, hemophilia and 
metabolic enzyme deficiencies (Lu, Choi et al. 2006, Bainbridge, Smith et al. 2008, 
Burnett and Hooper 2009, Nathwani, Tuddenham et al. 2011, Bainbridge, Mehat et al. 
2015, Chiriboga, Swoboda et al. 2016). Duchenne muscular dystrophy has been a 
popular focus for gene therapies due to a dearth of effective therapies and single gene 
defect. Multiple strategies targeted at the dystrophin gene have been employed: gene 
replacement, exon skipping and direct genome editing.  
Gene replacement involves administration of a DNA sequence for the missing or 
defective protein. Viral vectors have been extremely useful for delivering the dystrophin 
sequence due to their prolonged transgene expression. Adenovirus-mediated delivery 
to the GRMD model resulted in moderate gene expression; however, a significant 
humoral and cellular immune response diminished dystrophin expression by 2 months 
post-treatment (Howell, Lochmuller et al. 1998). On the other hand, gene delivery 
attempts using recombinant adeno-associated viruses (rAAVs) were much more 
successful. To account for the small packaging size of AAVs (<5 kb), truncated 
dystrophin constructs (“mini-dysrophin” or “micro-dystrophin”) were generated to include 
essential regions of the dystrophin protein (Wang, Li et al. 2000, Fabb, Wells et al. 
2002, Sakamoto, Yuasa et al. 2002, Fairclough, Wood et al. 2013). In a notable 
example, mini-dystrophin constructs encoding the NH2 terminal domain, cysteine-rich 
domain, central rod repeats (repeats 1 to 2 or 3 and 22 to 24) and variable hinge 
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regions were created (Wang, Li et al. 2000). These mini-dystrophin transgenes were 
packaged into the AAV2 capsid and injected intramuscularly into neonatal and adult 
mdx mice. Dystrophin and DAPC components at the sarcolemma were completely 
restored. As a result, dystrophic pathology was ameliorated, which was supported by 
normal myofiber morphology, increased membrane integrity, a reduction in centralized 
nuclei, decreased immune cell infiltration and absence of fibrosis. Greater 
improvements were observed with earlier intervention, but transgene expression was 
persistent at 6 months, regardless of age at treatment. A subsequent study reported 
that muscle from treated mdx mice showed increased contractile force, or the force 
generated by muscle (Watchko 2004).  
In a following study performed in GRMD dogs, a mini-dystrophin construct was 
packaged into the AAV9 capid, which exhibits high transduction in striated muscle, and 
administered intravenously (Kornegay, Li et al. 2010). Dystrophin was present in nearly 
100% of skeletal muscle and muscle from treated dogs largely mirrored murine 
histological findings. However, an innate immune response was detected. Coupled with 
transient immunosuppression, overall transgene expression was not affected and could 
be detected up to 2 years post-treatment. Studies using AAV6 to deliver a micro-
dystrophin transgene to GRMD dogs have reported similar results, noting an immune 
response as well (Wang, Storb et al. 2012). Still, the immune responses reported did 
not adversely affect dystrophic pathology nor abrogate overall therapeutic value of 
these treatments. This response ultimately may be attributed to disease-associated 
inflammation and an animal model-specific reaction (ex. canine neutralizing antibodies). 
To this end, a Phase I clinical trial evaluating AAV-delivered mini-dystrophin found that 
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the humoral immune response could be minimized by AAV capsid modification (Bowles, 
McPhee et al. 2012). Further investigation has helped to clarify the contribution of the 
AAV vector in these responses and possible areas for improvement, which will be 
discussed in a later section (see IV. Adeno-associated viruses).  
Exon skipping is another well-studied strategy that involves administration of 
antisense oligonucleotides (AONs), which hybridize to defective dystrophin precursor 
mRNA (premRNA) at specific splicing sites. Bound AONs would prevent splicing 
machinery from accessing these sites, effectively skipping certain exons to restore a 
normal open reading frame. The end product would be a truncated dystrophin protein to 
induce a milder phenotype as in BMD. Theoretically, most deletion, small and 
duplication mutations are amenable to skipping of one or two exons (79%, 91% and 
73%, respectively) (Aartsma and Rus 2009). Due to the relatively short circulation time 
of AONs, chemical modifications have been made to increase oligonucleotide stability. 
Most preclinical and clinical phase studies have used 2’-O-methyl oligoribonucleotide 
and morpholino-based AONs (Lu, Mann et al. 2003, Aartsma and Rus 2009, Clement, 
Knop et al. 2009, Yokota, Lu et al. 2009, Cirak, Arechavala-Gomeza et al. 2011). In one 
particular study, adult and neonatal mdx mice were injected with morpholino-based 
AONs to skip exon 23 (Fletcher 2006). Sarcolemmal dystrophin expression was 
observed in 36% of fibers after intramuscular injection into the tibialis anterior muscle. 
Localized improvements were observed, with less centrally nucleated fibers and 
reduced mononuclear infiltration adjacent to the site of transgene expression. In a study 
with dystrophic dogs, a cocktail of morpholino AONs targeting exons 6 and 8 splice sites 
was evaluated (Yokota, Lu et al. 2009). Widespread dystrophin expression was 
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observed, which was accompanied by improvements in dystrophic pathology and 
stabilization of clinical symptoms.  
Following promising preclinical results, several proof-of-concept clinical trials 
have been conducted in DMD boys (Kinali, Arechavala-Gomeza et al. 2009, Bowles, 
McPhee et al. 2012, Fairclough, Wood et al. 2013). A Phase I/II trial utilized a 
morpholino-based AON treatment targeted at exon 51, called Eteplirsen, which would 
be applicable to ~15% of patients. After treatment, patients expressed up to 32% of 
normal dystrophin levels. Results were dose-dependent and variable between patients, 
with some boys showing no changes in protein expression. In 2016, the FDA granted 
fast-track approval for Eteplirsen, which is contingent on evidence of functional 
improvements with treatment (Stein 2016). Nonetheless, the exon-skipping strategy 
faces major hurdles. AONs must be personalized for each mutation and each 
formulation would be considered an individual therapy subject to FDA approval. 
Oligonucleotides also suffer from poor uptake, which has been remedied by viral 
mediated delivery of exon-skipping sequences (Foster, Popplewell et al. 2012). Finally, 
the long-term effects associated with repeated oligonucleotide infusion are still unknown 
(Fairclough, Wood et al. 2013, Vila, Klimek et al. 2015). The recent approval of 
Nusinersen, an exon-skipping drug for spinal muscular atrophy, has strengthened hope 
in the field and may help to inform studies for future AON-based therapies for DMD 
(Dolgin 2017). 
Genome editing has garnered a great deal of attention due to the development of 
new tools that increase specificity of gene correction. Adapted from prokaryotes, the 
CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 system has 
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been used by several groups to permanently excise defective dystrophin exons in the 
host genome. This approach is similar to exon skipping in that a shorter dystrophin 
protein is produced. The genome editing machinery consists of the Cas9 endonuclease, 
which cleaves the genome, and a guide RNA (gRNA) that directs Cas9 to a desired 
location. In one study, these components were delivered in separate AAV vectors to 
adult and neonatal mdx mice, which restored dystrophin expression in ~67% of 
myofibers. As a result, nNOS activity was restored and muscle function significantly 
improved (Nelson, Hakim et al. 2016). Another group showed that CRISPR/Cas9 could 
be used to correct dystrophin in the germ line of mdx mice. In progeny with 81% allele 
correction, dystrophin levels were indistinguishable from wild-type muscle and the 
dystrophic symptoms did not develop. Correction of 17% of alleles also displayed 
dystrophin expression in the majority of fibers and a milder pathology (Long, McAnally 
et al. 2014). Nevertheless, remaining obstacles with this strategy are low rate of 
correction, off-target cutting and a potential immune response to Cas9 (Calos 2016). 
Further study is necessary to find ways to overcome these limitations for treatment of 
DMD patients. 
Vi. Surrogate therapies 
Despite significant success with dystrophin-targeted therapies, remaining 
challenges have pointed to an incomplete understanding of disease pathobiology. After 
micro-dystrophin rescue, mdx mice still experienced fatigue after mild exercise 
(Kobayashi, Rader et al. 2008). Additionally, full restoration of mini-dystrophin 
expression in GRMD dogs failed to combat the progression of cardiomyopathy and joint 
contractures (Kornegay, Li et al. 2010). Several studies have shown that the profound 
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muscle degeneration observed in dystrophic muscle results from the contribution of 
secondary diseases pathways that exacerbate the primary genetic defect (Mendell, 
Engel et al. 1971, Deconinck and Dan 2007, Rosenberg, Puig et al. 2015). These 
findings have fueled investigation into surrogate therapies, which address aspects of 
DMD pathology aside from dystrophin loss. Gene therapies have utilized  “booster 
genes” to ameliorate symptoms in the absence of dystrophin. Expression of booster 
genes targeting functional ischemia, inflammation, structural integrity, membrane 
instability, oxidative stress response and fibrosis have all shown impressive therapeutic 
benefit (Engvall and Wewer 2003). Two well-studied approaches will be discussed: 
improving muscle blood flow and increasing structural integrity.  
Studies have indicated that dystrophic muscle is burdened by functional 
ischemia, or insufficient blood flow (Sander, Chavoshan et al. 2000, Nelson, Rader et al. 
2014). Due to the displacement of nNOS at the sarcolemma, dystrophic muscle 
produces suboptimal levels of nitric oxide (NO), a potent vasodilator, in response to 
movement (Wehling, Spencer et al. 2001, Kobayashi, Rader et al. 2008). Reduced 
perfusion has been observed in DMD patients, which negatively impacted grip force 
(Nelson, Rader et al. 2014). Studies in rodents have also demonstrated that ischemia 
reproduced DMD lesions and was necessary for the development of the dystrophic 
phenotype (Mendell, Engel et al. 1971, Asai, Sahani et al. 2007). In one study, mdx 
mice were treated with rAAVs carrying the gene for vascular endothelial growth factor A 
(VEGFA) to increase capillary density. (Messina, Mazzeo et al. 2007). The VEGF family 
of growth factors serves as critical drivers of vascular formation during embryogenesis 
and post-natal growth. Binding of VEGFA with VEGF receptors is known to promote 
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endothelial cell migration, proliferation and survival, providing a framework for new 
vasculature. VEGFA also stimulates permeability, an effect that is dose-dependent and 
prominent in diseases such as cancer (Yancopoulos, Davis et al. 2000, Jain 2003). 
Localized expression of VEGFA increased capillary density in mdx muscle, particularly 
in regenerating regions, and reduced the number of necrotic fibers. Treatment also 
increased satellite cell activation and significantly improved forelimb strength (Messina, 
Mazzeo et al. 2007). The therapeutic value of increased muscle blood flow has been 
further supported by studies using pharmacological agents to induce vasodilation. 
Administration of phosphodiesterase 5 (PDE5) inhibitor, a potent vasodilator, improved 
cardiac function in mdx mice and also restored normal blood flow in DMD patients after 
exercise (Adamo, Dai et al. 2010, Nelson, Rader et al. 2014). While further investigation 
is necessary, mitigating functional ischemia appears to be a viable strategy for future 
DMD therapies. 
Surrogate therapies have also aimed to increase structural integrity of the 
myofiber aside from dystrophin. One strategy is to increase the expression of utrophin, 
which is an autosomal paralog of dystrophin. Utrophin is found in all tissues and is 
normally localized at the neuromuscular and myotendinous junction of mature muscle. 
Utrophin is similar in size (395 kDa) and primary structure to dystrophin, especially at 
the NH2, WW, cysteine rich and COOH terminal domains (Blake, Weir et al. 2002). Due 
to their structural homology, utrophin and dystrophin are believed to be functionally 
interchangeable, which may explain the milder phenotype of mdx (Deconinck, Rafael et 
al. 1997). While DMD patients also displayed utrophin increases in muscle, these levels 
were not sufficient for compensatory action (Khurana and Davies 2003). 
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Transgenic mdx mice that overexpressed full-length and a truncated utrophin at 
the sarcolemma did not develop any dystrophic symptoms. Furthermore, their muscle 
exhibited close to normal force generation (~80%) that persisted with repeated eccentric 
contractions, suggesting that utrophin and dystrophin are functionally redundant. 
Overexpression of utrophin also protected the myofiber from membrane damage and 
restored calcium homeostasis (Deconinck, Tinsley et al. 1997, Tinsley, Deconinck et al. 
1998). To determine if utrophin-targeted gene therapy would be beneficial, a micro-
utrophin construct was created encoding the NH2, central rod repeats (1 to 3, 22) and 
cysteine-rich domains. The construct was packaged into an AAV6 vector and 
administered to mdx; utrophin-/- mice. Treatment increased utrophin and DAPC 
localization at the sarcolemma, which improved muscle fiber morphology and 
decreased central nucleation. Serum CK levels were also significantly reduced with 
treatment. Motor function deficits were also ameliorated; force generation increased and 
muscle injury from eccentric force was lessened with treatment (Odom, Gregorevic et 
al. 2008). Pharmacological interventions to increase endogenous utrophin levels have 
also been explored. A small molecule drug, SMT C110, increases utrophin transcription 
and provided therapeutic benefit in mdx mice (Tinsley, Fairclough et al. 2011). A clinical 
trial in DMD boys is currently underway (Tinsley, Robinson et al. 2014). 
V. MicroRNA-206 
 Dysregulated microRNA profiles have been associated with a number of 
diseases, including schizophrenia, cardiac hypertrophy and cancer (Soifer, Rossi et al. 
2007). MicroRNAs (miRNAs or miRs) are short (~21-24 bp) RNA molecules that serve 
as important regulators of gene expression. MicroRNA sequences are located in the 
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intronic region of protein encoding genes or in long non-coding RNAs. The majority of 
miRs are transcribed along with their respective protein encoding genes from a common 
promoter by RNA polymerase II (Pol II). Once transcribed, the miRNA hairpin within the 
primary mRNA (pri-mRNA) is recognized and cleaved by the nuclear microprocessor 
complex, composed of the ribonuclease enzyme Drosha and RNA-binding protein 
DGCR8. The resulting pre-miRNA (~60 nt) is recognized by exportin-5 and transported 
into the cytoplasm, where it is cleaved by Dicer into ~22 nt duplexes. One of the duplex 
strands is preferentially incorporated into the RISC complex with the help of cofactors 
such as TAR RNA binding protein (TRBP) and protein activator of the interferon-
induced protein kinase (PACT). RISC will then cleave, degrade or preventing translation 
of hundreds of target transcripts, which is dictated by hybridization of the incorporated 
mature miRNA with complementary sequences in the 3’ untranslated region (UTR) in 
the mRNA (Soifer, Rossi et al. 2007). 
 Four muscle-specific miRNAs, or myomiRs, have been identified: miR-1, miR-
206, miR-133 and miR-208. These myomiRs play important roles in regulating gene 
expression in skeletal and cardiac muscle proliferation, differentiation and function. 
Expression of myomiRs is controlled by myogenic transcription factors (ex. SRF, MEF2 
and MyoD) that direct transcription from gene clusters located on chromosome 20 (miR-
1-1 and miR-133a-2), chromosome 18 (miR-1-2 and miR-133a-1) and chromosome 6 
(miR-206 and miR-133b). Due to their involvement in multiple signaling pathways in 
muscle, strict control of myomiR expression is necessary (Williams, Liu et al. 2009).  
 A shared microRNA signature was discovered in DMD and mdx muscle, 
characterized by significant changes in 11 miRNAs. Levels of myomiRs miR-1 and miR-
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206 were markedly decreased and increased, respectively, in dystrophic muscle 
compared to normal controls (Greco, De Simone et al. 2009). To ascertain whether 
dystrophin rescue normalized miRNA expression, mdx mice and DMD myotubes were 
treated with viral vectors encoding sequences to induce skipping of defective exons. In 
both cases, dystrophin rescue restored wild-type levels of all affected miRNAs, but not 
miR-206. Moreover, deregulation of miRs, such as miR-1 and miR-29, was linked to the 
abnormal oxidative stress response and fibrosis, respectively, typically observed in 
dystrophic muscle (Cacchiarelli, Martone et al. 2010). Thus, the miR-206 upregulation in 
DMD occurs independently of dystrophin loss and its contribution to disease pathology, 
if any, remains unclear. 
Skeletal muscle-restricted miR-206 is highly expressed in regenerating muscle 
and serves as an important mediator of satellite cell differentiation via Pax7 inhibition 
(Chen, Tao et al. 2010). Transgenic miR-206 knockout mice develop normally, yet 
exhibit impaired regeneration in response to muscle damage. MicroRNA-206 gradually 
decreases with continued differentiation, but is relatively one of the most abundant miRs 
in adult skeletal muscle (McCarthy 2008). Compared to normal muscle, miR-206 levels 
are significantly upregulated in the mdx muscle and particularly in the diaphragm, which 
closely mirrors DMD pathology (McCarthy, Esser et al. 2007, Greco, De Simone et al. 
2009). Elevated levels have also been discovered in myotonic dystrophy type I (DMI) 
patients (Gambardella, Rinaldi et al. 2010). Previous attempts have been made to 
elucidate the role of miR-206 in both DMD and amyotrophic lateral sclerosis (ALS) 
(Williams, Valdez et al. 2009, Liu, Williams et al. 2012). In these studies, mdx and ALS 
model mice were crossed with miR-206 knockout mice. Loss of miR-206 disrupted 
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skeletal muscle and neuromuscular synapse regeneration in each model, respectively. 
MicroRNA-206(-/-)/mdx mice displayed a drastically worsened phenotype, suggesting a 
reparative role for miR-206. Since proper satellite cell functioning is necessary for 
adequate muscle regeneration in response to muscle damage, the additional loss of 
miR-206 may compound existing deficiencies in dystrophic muscle precursors. Still, 
these studies have only focused on myoblasts and do not address elevated miR-206 
levels in mature muscle. Transgenic knockout also confound the possible contribution of 
other cell types present in the muscle. While miR-206 levels have been shown to be 
particularly high in the diaphragm compared to other muscle groups, the level myogenic 
proliferation in the diaphragm does not differ significantly from the hindlimb muscles 
(Anderson, Garrett et al. 1998, McCarthy, Esser et al. 2007). The notion that 
regenerating muscle is solely responsible for observed miR-206 levels is thus subject to 
question. Altogether, these findings denote a limited understanding of the function of 
miR-206 in dystrophic muscle overall, which warrants further study. 
Interestingly, there is overlap between confirmed miR-206 targets and genes 
used for surrogate therapies. For example, studies in zebrafish have shown that miR-
206 negatively regulates VEGFA and angiogenesis. Knockdown of miR-206 increased 
VEGFA expression and subsequently increased endothelial cell proliferation (Stahlhut, 
Suarez et al. 2012, Lin, Lee et al. 2013). Utrophin is another target of miR-206, which 
contains a miR-206 binding sequence that is shared between mice, humans and dogs. 
Induction of microRNA-206 expression in vitro has been shown to inhibit utrophin via its 
3’ UTR (Rosenberg, Georges et al. 2006). While elevated miR-206 levels are necessary 
for regulating differentiation-associated gene expression in muscle precursor cells, its 
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abnormal expression in dystrophic muscle may be detrimental by repressing proper 
responses to muscle damage. Altogether, miR-206 may be involved in downregulating 
beneficial gene expression, which points to a possible pathological role in DMD. 
VI. Adeno-associated virus 
Found ubiquitously in nature, the wild-type AAV is a small (~20 nm), non-
enveloped Parvovirus with a DNA genome of about 4.8 kb. AAVs are naturally 
replication-defective, requiring helper virus functions for productive infection. Unlike 
other viruses commonly used for gene transfer, such as adenovirus and retroviruses, 
AAVs are non-pathogenic and have not been associated with any known disease. 
Recombinant adeno-associated viruses have been used extensively in basic research 
and therapeutics for their tissue tropism, favorable safety profile and ability to stably 
transduce tissue. These attributes have collectively made AAV-based gene therapies 
attractive for muscle diseases, such as DMD (Mezzina and Merten 2011). 
The recombinant AAV genome is composed of an expression cassette 
containing a promoter, gene of interest (GOI) and poly-A signal, which is flanked on 
either side by inverted terminal repeats (ITRs). The ITRs are the only remnants of the 
wild-type AAV genome and are essential for proper orientation and packaging into the 
capsid (Mezzina and Merten 2011). To restrict expression to muscle, muscle-specific 
transcriptional regulatory elements have been utilized, such as the muscle creatine 
kinase (MCK) promoter and α-myosin heavy chain enhancer (Salva, Himeda et al. 
2007). Gene therapies have also taken advantage of different AAV capsid variants, or 
serotypes, which display distinct receptor binding, tissue tropism and antigenicity. 
Twelve naturally-occurring serotypes, AAV1 through AAV12, have been isolated to date 
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(Asokan, Schaffer et al. 2012). AAV2 was the first identified serotype and has been 
used most frequently in muscular dystrophy trials. However, AAV1, AAV6, AAV7, AAV8 
and AAV9 all display naturally high tropism in post-mitotic muscle, exceeding that of 
AAV2. These serotypes have demonstrated exceptional transduction in muscle (>90%) 
after intravenous delivery, which would ensure efficient delivery to afflicted tissue (Qiao, 
Koo et al. 2011).  
While rAAV gene therapies for DMD have many advantages, they still face 
vector- and disease-specific hurdles. AAV vectors have a limited packaging capacity of 
~5 kb, which cannot accommodate the full-length dystrophin gene. Additionally, as 
many as 72% of the population has pre-existing neutralizing antibodies to the AAV2 
serotype, which may obstruct AAV delivery to target tissue (Boutin , Calcedo, 
Vandenberghe et al. 2009). Employing an alternative serotype or mutant capsids are 
two strategies to avoid the Nab response, and can also work to reduce off-target effects 
and increase genetic payload (Kotterman and Schaffer 2014). Although the use of a 
mutant capsid minimized immunogenicity in a trial with DMD patients, there is also 
evidence of dystrophin-specific T cells present in some DMD patients (Mendell , 
Campbell  et al. 2010, Bowles, McPhee et al. 2012). Thus, a greater understanding of 
DMD pathology and alternative strategies for treatment is necessary. 
VII. Hypothesis & Specific Aims 
 As outlined in the previous sections, the lack of effective treatments for 
Duchenne muscular dystrophy warrants investigation into responsible pathological 
mechanisms and alternative therapeutic strategies. Challenges with dystrophin-targeted 
therapies have highlighted the role of secondary disease mechanisms, which 
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exacerbate dystrophic pathology. Surrogate therapies that address these mechanisms 
have significantly improved dystrophic symptoms. Studies have shown that microRNAs 
are dysregulated in dystrophic muscle and elevated microRNA-206 levels have been 
observed in muscle from both mdx mice and DMD patients compared to normal 
controls. However, the contribution of miR-206 in mature muscle to pathology is 
unknown. Overexpression of verified targets, VEGFA and utrophin, has demonstrated 
therapeutic benefit in animal models of DMD, pointing to pathological role for miR-206. 
Thus, I hypothesize that (1) miR-206 inhibits expression of therapeutic genes VEGFA 
and utrophin and (2) downregulation of miR-206 via an AAV9 vector ameliorates 
associated secondary disease pathways to improve dystrophic pathology. Focusing on 
two well-studied disease mechanisms, I will test these hypotheses in the following Aims:  
(1) Deternine the role of miR-206 on muscle vascularization in mdx mice via VEGFA. 
(2) Examine the role of miR-206 on muscle pathology in mdx mice via utrophin. 
  
 24 
 
Table 1. Classification of the muscular dystrophies. Adapted from (Khurana and 
Davies 2003). 
  
2
5
 
 
  
2
6
 
Figure 1.1. Schematic diagram of the dystrophin-associated protein complex (DAPC) at the muscle membrane 
(sarcolemma). Dystrophin (in yellow) forms a linkage between inner actin filaments and extracellular matrix through its 
association with the transmembrane DAPC. Adapted from (Fairclough, Wood et al. 2013).   
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CHAPTER 2: DOWNREGULATION OF MICRORNA-206 IMPROVES MUSCLE 
VASCULARIZATION IN MDX MICE 
I. Introduction 
Several studies have demonstrated hemodynamic differences in muscle from 
normal patients and those with Duchenne muscular dystrophy (Sander, Chavoshan et 
al. 2000, Nelson, Rader et al. 2014). Dystrophin loss from the muscle membrane results 
in sarcolemmal delocalization of neuronal nitric oxide synthase (nNOS), which produces 
nitric oxide (NO) in response to skeletal muscle contraction. NO induces vasodilation by 
attenuating sympathetic vasoconstriction to allow for adequate blood flow (Grange, 
Isotani et al. 2001). Without proper localization of nNOS, dystrophic muscle suffers from 
functional ischemia, or insufficient blood flow that cannot meet metabolic demands. 
Compared to normal controls, mdx mice and DMD patients display reduced 
compensatory muscle oxygenation after exercise (Sander, Chavoshan et al. 2000, 
Latroche, Matot et al. 2015). Studies have also shown that functional ischemia is 
necessary for muscle necrosis in dystrophin-deficient mice, supporting a “two-hit” 
mechanism in dystrophic pathology (Rando 2001, Asai, Sahani et al. 2007). Therapeutic 
agents that induce vasodilation or increase muscle vascularization significantly 
improved muscle pathology as well as motor function in DMD and mdx mice (Ennen, 
Verma et al. 2013). Therefore, counteracting functional ischemia is a viable strategy for 
alleviating dystrophic symptoms. 
Vascular endothelial growth factor A (VEGFA) is an important mediator in 
angiogenesis, stimulating endothelial cell proliferation, migration and survival 
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(Yancopoulos, Davis et al. 2000). AAV-mediated delivery of VEGFA to the mdx bicep 
significantly increased capillary density in regenerating regions and also reduced 
necrotic regions in muscle. VEGFA overexpression also significantly improved forelimb 
strength and increased muscle regeneration (Messina, Mazzeo et al. 2007). Still, 
VEGFA expression must be closely regulated as excessive levels may cause an 
imbalance of angiogenic signals. While many endothelial cells are recruited after 
administration of large doses of VEGFA, vessels are disorganized and leaky and may 
result in hemangioma formation (Carmeliet 2000). Thus, systemic application of VEGFA 
required to treat all of the muscle poses risks. Increasing endogenous expression of 
VEGFA may be a better alternative to avoid persistent overexpression from additional 
copies of the gene.  
VEGFA is a target of microRNA-206, which is overexpressed in dystrophic 
muscle, yet its function in mature muscle is not well-understood. Studies in zebrafish 
have shown that miR-206 inhibits VEGFA expression and that disruption of miR-206 
expression increased levels of VEGFA, stimulating angiogenesis (Stahlhut, Suarez et 
al. 2012, Lin, Lee et al. 2013). Thus, microRNA-206 may work to prevent endogenous 
VEGFA expression, contributing to functional ischemia in dystrophic muscle.  
In this chapter, I aimed to determine whether miR-206 plays a role in DMD 
pathogenesis by inhibiting VEGFA expression and impeding proper muscle 
vascularization. First, I demonstrated that miR-206 can be effectively downregulated 
with an antisense construct, “anti-miR-206.” The anti-miR-206 construct was packaged 
into the AAV2 capsid to determine specificity in vitro and then into the AAV9 capsid and 
administered to mdx mice to examine therapeutic benefit. Functional improvements 
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were evaluated by rotarod, grip force and treadmill testing. VEGFA levels were assayed 
to determine the effect of treatment on miR-206 target expression. Capillary density was 
measured to determine the angiogenic effect of VEGFA. Finally, vessel permeability 
was investigated to determine the influence of VEGFA expression on endothelial cell 
organization and function. Findings from these studies could help to clarify the role of 
miR-206 and corroborate a new approach for treating DMD.  
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II. Materials and methods 
AAV vector construction and production 
 
 Four tandem repeats of the antisense sequence against miR-206 (5’-
CCACACACUUCCUUACAUUCCA-3’) were previously generated through the UNC 
Nucleic Acids Core Facility. This sequence was cloned into the 3’ untranslated region of 
a full length or truncated GFP coding sequence in the pEMBOL AAV vector plasmid, 
which contains ITRs for efficient viral packaging. The completed construct, “anti-miR-
206,” or the truncated GFP without miR-206 binding sites, “1/2gfp,” were packaged into 
the AAV2 (in vitro analyses) or AAV9 (in vivo studies) capsid via triple-plasmid 
transfection in HEK293 cells. Briefly, 293 cells were propagated in Dulbecco’s modified 
Eagle’s medium (DMEM) in 15 cm plates supplemented with 10% fetal bovine serum 
(FBS) at 37°C in 10% CO2/90% air. When cells reached 90-95% confluency, each plate 
was transfected with 18.7 μg vector plasmid (containing anti-miR-206 sequence), 25 μg 
Adenovirus helper plasmid and 6.25 μg AAV9 packaging plasmid diluted in a solution 
consisting of 2 ml 0.25M CaCl2 and 2 ml cold HBS buffer (50 mM HEPES, 280 mM 
NaCl and 1.5 mM NaH2PO4; pH 7.1). For each virus preparation, 30 to 40 15 cm plates 
were used. Eight to twelve hours later, the medium was replaced with fresh DMEM 
supplemented with 2% FBS. At 60 to 68 hours post-transfection, cells and media were 
collected for AAV purification. Cells were resuspended in suspension buffer I (50mM 
HEPES, 150 mM NaCl, 50 mM NaH2PO4, 2 mM MgCl2, 2.5 mM KCl, pH 8.0) and 
freeze-thawed 3 times. The cell lysate was treated with DNAse (100 units/ml) and 
RNase A (4 units/ml) and incubated at 37°C for 1 hour. Debris was removed by 
centrifugation at 25,000 rpm at 4°C for 25 minutes. PEG-8000 and NaCl solution were 
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added to the clarified medium and incubated at 4°C overnight. For the culture medium, 
PEG-8000 and NaCl were added and incubated at 4°C overnight. The cell lysate and 
medium were centrifuged at 25,000 rpm for 30 minutes and resuspended in fresh 
suspension buffer. The solutions were combined and ultracentrifuged at 31,000 rpm for 
16 hours in a CsCl density gradient. The AAV band was collected and subjected to a 
second round of CsCl density gradient ultracentrifugation at 38,000 rpm for 48 hours. 
The AAV band was collected in 1 ml aliquots and stored at -80°C. 
 AAV titer was quantified by dot blot hybridization. Ten microliters of AAV stock 
was added to 200 μl DMEM and treated with 50 μg/ml Dnase I at 37°C for 1 hour to 
degrade unencapsidated DNA. Then, 0.5 mg/ml proteinase K in 200 μl proteinase K 
buffer (20 mM Tris Cl pH 8.0, 20 mM EDTA pH 8.0, 1% SDS) was added and the 
sample was incubated at 55°C for 1 hour to degrade the capsid. The vector DNA was 
precipitated in 70% ethanol, 135 μmol sodium acetate and glycogen (40 μg) and 
centrifuged at 17,000 x g at 4°C for 10 minutes. The resultant pellet was resuspended in 
alkaline buffer (0.4 M NaOH and 10 mM EDTA pH 8.0) and bound to a hybridization 
transfer membrane (PerkinElmer). A standard of the original vector plasmid was applied 
to the same membrane. A biotin-labeled probe against CMV was hybridized to the 
membrane at 55°C overnight. Bound probe was detected using the North2South 
Chemiluminescent Nucleic Acid Hybridization and Detection Kit (Pierce). AAV titers 
were in the range of 1012 to 1013 vector genomes (vg)/ml. Virus intended for treatment 
were then dialyzed in dialysis buffer (2% mannitol, 6 mM MgCl2 and 1X PBS) for a total 
of 8 hours with a buffer change every 2 hours. 
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In vitro specificity assay 
 MicroRNAs silence their target mRNAs through binding complementary sites 
within the 3’ UTR and recruiting factors that degrade the mRNA or prevent translation. 
We hypothesized that the anti-miR-206 construct serves as a mock mRNA target for 
miR-206. To determine if miR-206 specifically bound and prevented expression of the 
GFP marker upstream of the anti-miR-206 sequence, we performed an in vitro 
specificity assay. CMV-GFP-anti-miR-206, CMV-pre-miR-206 and CMV-pre-miR-124 
sequences were packaged into the AAV2 capsid by the triple transfection method 
described above (AAV vector construction and production). HEK293 cells were 
transduced with AAV2-CMV-GFP-anti-miR-206 (MOI: 106 vg/cell) alone or in 
combination with AAV2-pre-miR-206 (1X MOI: 106 vg/cell or 2X MOI: 2 x 106 vg/cell) or 
AAV2-pre-miR-124 (MOI for 1X: 106 vg/cell). After 48 hours, GFP expression was 
examined using a Nikon Eclipse TE300 microscope (Nikon USA) and a SPOT RT Slider 
camera (Diagnostic Instruments, Inc.). 
Animals 
Breeding pairs of homozygous females and hemizygous males for the mdx 
genotype (C57BL/10ScSn-Dmdmdx/J) were obtained from the Jackson Laboratory (Bar 
Harbor, ME). Male mdx mice were treated with PBS or 1012 vg of AAV9-anti-miR-206 at 
8 weeks of age via tail vein injection. Wild-type C57/B6 mice were also used for 
comparison. Animals were anesthetized with 2.5% avertin (total dose of 250 mg/kg) and 
sacrificed at 1, 3 and 5 months post-treatment. Extracted muscle was snap-frozen in 
liquid nitrogen-cooled isopentane. Extracted muscle was stored at -80°C for future 
analysis. All experiments using mice were approved by the Institutional Animal Care 
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and Use Committee at the University of North Carolina at Chapel Hill and in accordance 
with the National Institute of Health guidelines. 
Motor function testing 
 AAV9-anti-miR-206, AAV9-1/2GFP (control vector) and PBS treated mice were 
subjected to grip force test, rotarod testing and treadmill running to examine motor 
function at baseline, then 1 month after vector administration and repeated every two 
weeks until sacrifice. Forced exercise also increases muscle damage in mdx hindlimb, 
which otherwise shows only mild dystrophic symptoms, for better comparison of 
untreated and treated groups. Grip force test was used to measure the forelimb strength 
of the mice. A grip force meter (Chantillon, model DFIS-2) was used. Mice were held by 
the tail and allowed to grasp the attached bar with their front paws. The mice were then 
pulled back quickly to measure grip force. Rotarod testing was performed on a rotarod 
machine (Med Associates, Inc.) to examine balance, motor coordination and grip 
strength. Mice were placed on the rod and allowed to acclimate for 1 minute. The rod 
was then accelerated from 4 to 40 rpm over 5 minutes. The time to first fall was 
recorded and used for analysis. Treadmill running was performed to test endurance. 
Mice were allowed to acclimate to the treadmill (Harvard Apparatus) at a speed of 5 
meter/min (m/min) for 60 seconds. The speed was increased to 10 m/min for 15 
minutes and then increased by 5 m/min after every 10 minutes. The shock grids at the 
end of each lane were set to 1 mA to encourage mice to run until exhaustion. If a mouse 
failed to run and remained on the grid for 10 seconds, the test was terminated and the 
mouse was removed immediately. The total run time at each speed was recorded to 
calculate total distance for statistical analysis. 
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MicroRNA-206 quantification 
 Total RNA was extracted from diaphragm muscle using the TRIzol reagent 
(Thermo Fisher Scientific) and stored at -80°C until further use. A cDNA template for 
microRNAs was created using the miRNA 1st-Strand cDNA Synthesis Kit (Agilent 
Technologies). The resulting template was diluted 1:5 for quantitative PCR (qPCR). 
Reactions were set up using PowerUp SYBR Green Master Mix (Thermo Fisher 
Scientific) according to the manufacturer’s protocol and run in an Applied Biosystems 
7300 Thermocycler. MicroRNA-206 expression was quantified relative to ubiquitous 
miR-26b. The primers used were as follows: miR-206 (5’-
GGCTGGAATGTAAGGAAGTGTGTGG-3’), endogenous miR-26b (5’-
GGCCGTTCAAGTAATTCAGGATAGGT-3’) and a universal reverse primer provided 
with the cDNA synthesis kit (proprietary sequence). Expression was depicted as fold-
change over control. 
VEGF-A transcript quantification 
 A cDNA template was reverse transcribed from total RNA using the High-
Capacity Reverse Transcription kit (Thermo Fisher Scientific). The resulting template 
was diluted 1:5  for qPCR. Reactions were set up using PowerUp SYBR Green Master 
Mix (Thermo Fisher Scientific) according to the manufacturer’s protocol and run in an 
ABI 7300 Thermocycler. VEGF-A expression was quantified relative to ubiquitous beta-
actin. The primers used were as follows: VEGF-A (forward: 5’-
GGCCTCCGAAACCATGAACTT-3’ and reverse: 5’-TGGGACCACTTGGCATGGTG-3’) 
and beta-actin (forward: 5’-ATCACTATTGGCAACGAGCG-3’ and reverse: 5’-
ACTCATCGTACTCCTGCTT-3’). Expression was depicted as fold-change over control. 
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Western blot 
 Tibialis anterior (TA) muscle was homogenized in cold RIPA buffer (150 MM 
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) 
using a tissue homogenizer (Tekmar Ultrasonic Processor model TM130). Protein 
concentration was determined by BCA assay (Thermo Fisher Scientific). For Western 
blotting, 20 μg of protein from each sample was prepared in 6X loading buffer (375 mM 
Tris pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 0.06% bromophenol blue) and heated 
at 95°C for 5 minutes. Proteins were separated by SDS-PAGE and wet transferred onto 
a PVDF membrane using the Bio-Rad Mini-PROTEAN II system. Membranes were 
blocked in 5% milk in 1% TBS-Tween 20 (TBS-T) for 1 hour and incubated with either 
rabbit polyclonal antibody against VEGF-A (Abcam, catalog #ab46154, 1:1000) or rabbit 
polyclonal antibody against GAPDH (Sigma-Aldrich, cat. # G9545, 1:10,000) diluted in 
3% bovine serum albumin (BSA) in 1% TBS-T overnight at 4°C. Membranes were 
washed 3 times for 10 minutes in 1% TBS-T and then incubated with anti-rabbit IgG 
conjugated to horseradish peroxidase (Sigma-Aldrich, A0545, 1:5,000 for VEGF-A and 
1:10,000 for GAPDH) in 5% milk. Blots were developed using the Western Lightening 
Pro chemiluminescence kit (PerkinElmer) and visualized using the FluorChem M 
imaging system (ProteinSimple). 
Vessel quantification 
 Cryosections of diaphragm muscle 10 μm thick were made. At room temperature, 
slides were washed in PBS for 10 minutes then blocked in 10% horse serum for 1 hour. 
The muscle basal lamina was immunostained with a rat anti-laminin α2 antibody 
(Sigma-Aldrich, L0663, 1:500) in 1% horse serum in PBS for 1 hour and washed with 
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0.5% PBS-T 3 times for 5 minutes each. Anti-rat IgG conjugated to Alexa Fluor 488 dye 
(Molecular Probes, #A21470) and a Griffonia simplicifolia I lectin (GSLI) conjugated to 
rhodamine dye (Vector Laboratories, #RL-1102) for staining endothelial cells were 
diluted in 1% horse serum and used to incubate slides for 1 hour. Slides were washed 
with 0.5% PBS-T 3 times for 5 minutes each and mounted with aqueous mounting 
media (Gel/Mount, Biomeda). Slides were visualized using a Zeiss Axiovert 200M 
Confocal Microscope and images were taken using an AxioCam MRm camera. Images 
were processed using AxioVision Rel 4.6 and analyzed using ImageJ software. 
Miles assay 
 Evans blue dye (EBD), an azo dye with high affinity for serum albumin, was used 
for Miles assay to test vessel function/integrity in mice. While normal vessels are 
impermeable to albumin, leaky vessels allow albumin and thus dye to disperse into the 
muscle parenchyma (Radu and Chernoff 2013). A 10 mg/ml solution of EBD was made 
in PBS and 2 mg total was injected in mice via the tail vein. After 30 minutes, mice were 
anesthetized with i.p. injection of 2.5% avertin and cervically dislocated. Muscle 
dissection was performed as quickly as possible to avoid increased vessel permeability 
after death. Each dissection was performed within 15 minutes. Muscle was weighed, 
placed in 500 μl formamide and incubated at 55°C for 24 hours to fully extract dye. A 
standard was created with EBD in formamide was run concurrently with samples in a 96 
well plate. EBD absorbance was measured at 550 nm using the Perkin Elmer Victor2 
1420 Multi-label Counter/Plate-reader. 
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Statistical analysis 
 Graphs were generated and statistical analysis was performed using GraphPad 
5.0 software. Unpaired, two-tailed t-tests with Welch’s correction were performed when 
comparing two groups. One-way ANOVA was performed to determine treatment effect 
for Miles assay experiments. P values <0.05 were considered statistically significant. 
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III. Results 
Anti-miR-206 specifically binds miR-206 
 AAV vector plasmids were generated encoding the “anti-miR-206” sequence 
(Fig. 1A). A CMV promoter drove the expression of either GFP or a truncated GFP gene 
(for in vivo studies, not shown), followed by four tandem repeats of the exact antisense 
sequence against miR-206. Specificity for miR-206 was tested by packaging the anti-
miR-206 construct, the pre-miR-206 sequence and non-specific miR-124 sequence into 
the AAV2 capsid to transduce HEK293 cells (Fig. 1B). In AAV2-GFP-anti-miR-206 
transduced cells (first row), GFP levels were high, which suggests that the construct 
was efficiently packaged and the AAV vector was fully functional. In addition, cells did 
not show any signs of stress, such as contraction or cell death, following AAV 
transduction. Co-transduction with an equal amount of AAV2-pre-miR-206 greatly 
diminished GFP expression (second row), while expression was completely inhibited 
with additional pre-miR-206 (third row). Conversely, co-transduction of AAV2-GFP-anti-
miR-206 and non-specific AAV2-pre-miR-124 (fourth row) had no effect on GFP 
intensity. Thus, miR-206 specifically decreased expression of a GFP gene containing 
anti-miR-206 sequences in its 3’ untranslated region. 
Motor function improvements with anti-miR-206 treatment 
 PBS, AAV9-1/2GFP or AAV9-anti-miR-206 (1012 vg per mouse) were tail vein 
injected into 8 week-old mdx mice. One month following treatment, motor function 
testing was performed every two weeks until sacrifice. Anti-miR-206 treated mice 
demonstrated a significant increase in rotarod run times compared to PBS treated mice 
at 1 month post-treatment (Fig. 2A, untreated mean = 90.95 + 95 sec, sham vector 
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mean = 116.2 + 28.83 sec, treated mean = 150.9 + 18.61 sec, **p = 0.0105). While 
there was no major distinction at 3 months (Fig. 2B, PBS mean = 148.7 + 18.78 sec, 
sham vector mean = 151.3 + 12.16 sec, treated mean = 164.4 + 16.69 sec), anti-miR-
206 treated mice again performed significantly better (201.1 + 25.86 sec) than the 
untreated groups (90.25 + 20.70 sec and 95.40 + 12.24 sec, for PBS and vector control) 
at 5 months post-treatment (Fig. 2C, **p = 0.0044 and **p = 0.0038 for PBS and vector 
control). Over the course of 5 months, rotarod run time in untreated mdx mice was 
stagnant, with only a slight increase at 3 months. On the other hand, miR-206 reduction 
appeared to positively impact run time within the given time span. Grip force testing did 
not reveal any significant differences in strength between the groups until 4 and 5 
months post-treatment (Fig. 2D, 4 month PBS mean = 74.61 + 8.379 g, vector control 
mean = 69.55 + 14.05 g, treated mean = 96.24 + 4.867 g, *p = 0.0372 and *p 0.0277 
between treated and PBS and vector control, respectively. 5 month PBS mean = 79.49 
+ 9.808 g, sham vector mean = 67.63 + 18.875 g, treated mean = 106.9 + 7.345 g, *p = 
0.0376 and *p = 0.0455 between treated and PBS and vector control, respectively). At 3 
months, control mice began to experience a decline in strength, while treated mice 
continued to improve. In contrast, no obvious differences in treadmill running were seen 
between the groups over the course of 5 months (Fig. 2E, 2F, 2G). 
MicroRNA-206 levels in the muscle 
 Since no differences were observed between the PBS and control vector groups, 
the PBS group was considered the control or “untreated” group. MicroRNA-206 levels in 
the diaphragm muscle were investigated by relative qPCR in WT, mdx and mdx treated 
with AAV9-anti-miR-206. At the 1 month timepoint, dystrophic muscle miR-206 levels 
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were significantly greater than the WT, with a difference of ~4-fold (Fig. 3A, **p=0.0055, 
n = 6). Anti-miR-206 treatment reduced the amount of miR-206 in the diaphragm by 
about half, but considerable variation between treated samples was observed 
(p=0.2891, n = 6). Two months later, WT levels were still low, yet a substantial increase 
in miR-206 was detected in untreated mdx (Fig. 3B, ***p < 0.0001, n = 6). Vector 
treatment significantly decreased miR-206 by almost half (*p=0.0341, n = 6). However, 
there was no noticeable difference between the treated and untreated mdx at 5 months 
(Fig. 3C, p=0.9753, n = 6). 
VEGFA expression increases with treatment 
 VEGFA expression was first examined using relative qPCR to measure transcript 
levels in WT, mdx and treated mdx diaphragm. At 1 month, VEGF mRNA levels were 
significantly lower in the dystrophic diaphragm (Fig. 4A, *p = 0.0198, n = 6). With 
treatment, transcript levels appeared to increase albeit not significantly (untreated vs. 
treated, p = 0.0509, n = 6). Two months later, a significant ~2-fold increase in VEGF 
transcripts was found in the treated group vs. the untreated (Fig. 4B, **p = 0.0026, n = 
6), surpassing expression of the WT. This 2-fold increase was sustained until the 5 
month timepoint; however, this difference was not statistically significant (Fig. 4C, p = 
0.0683, n = 6). Within the given timeframe, mdx VEGF transcript levels were 
consistently (~2-fold) lower than the WT. A significant decrease was again observed 
between WT and mdx muscle (Fig. 4C, ***p < .0001, n = 6) at 5 months. 
 The amount of VEGFA protein was assayed by Western blot at tibialis anterior 
muscle samples at 1 month post-treatment (Fig. 5). Bands were observed at ~35 kDa, 
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which is indicative of ubiquitous VEGFA-164 isoform expression. A noticeable increase 
in VEGFA was observed with treatment compared to WT and untreated mdx. 
Increased capillary density with miR-206 reduction 
 To determine if VEGF expression induced angiogenesis, the number of 
capillaries per muscle fiber was quantified in the diaphragm. At 1 month, there was no 
obvious difference in vessel density between the untreated and treated groups (Fig. 
6A). A statistically significant decrease in capillary density was found between WT 
(mean = 2.184 + 0.1108) and mdx (mean = 1.788 + 0.0551) muscle (*p = 0.0495, n = 
6), but not in the treated sample (mean = 1.817 + 0.0333, n = 6). Capillary density in WT 
and treated muscle stayed fairly consistent at 3 months (Fig. 6B). In contrast, capillary 
numbers were further reduced in the mdx (mean = 1.503 + 0.0581) compared to WT 
(mean = 2.347 + 0.1022, ***p = 0.0008, n = 6) as well as treated mdx muscle (mean = 
1.982 + 0.0672, ***p < 0.0001, n = 6). A significant difference was also observed 
between WT and treated mdx groups (WT mean = 2.141 + 0.1282, *p = 0.0244, n = 6). 
At 5 months, vessels were again more numerous in the treated vs. untreated mdx 
muscle (2.123 + 0.2065 vs. 1.574 + 0.0708, *p = 0.0258, n = 6). Significantly fewer 
capillaries were found in the untreated muscle compared to the WT (**p = 0.0043, n = 
6).  
Vessel permeability is reduced with treatment 
 Vessel permeability in response to treatment was determined by Miles assay 
after 1, 3 and 5 months in quadriceps (QUAD), hamstring (HAM), gastrocnemius (GAS) 
and tibialis anterior (TA) muscles. In WT muscle overall, Evans blue dye (EBD) content 
was fairly consistent across muscle groups at all timepoints (1 month mean = 0.01753 + 
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0.001089 ng/mg, 3 months mean = 0.02460 + 0.001015 ng/mg, 5 months mean = 
0.01796 + 0.001171 ng/mg). EBD content in dystrophic muscle was significantly greater 
than WT (1 month mean = 0.03021 + 0.003278 ng/mg and *p = 0.0349, 3 months mean 
= 0.03548 + 0.002087 ng/mg and **p = 0.0094, 5 months mean = 0.02788 + 0.002463 
ng/mg and *p = 0.0220). A significant decrease in EBD was found in treated muscle at 3 
and 5 months post-treatment compared to the untreated group (3 month mean = 
0.02490 + 0.002746 ng/mg and *p = 0.0278, 5 month mean = 0.01895 + 0.001904 
ng/mg and *p = 0.0351).  At 1 month post-treatment, EBD levels were lower in anti-miR-
206 treated muscle (mean = 0.02073 + 0.002114 ng/mg), but this was not statistically 
significant (p = 0.0592). Two-way ANOVA analysis revealed that these results were 
dependent on treatment only (1 month ***p = 0.0008, 3 months *p = 0.0101, 5 months 
*p = 0.0129) and not muscle group (1 month p = 0.0881, 3 month p = 0.3252, 5 month p 
= 0.5205). In addition, there was no significant interaction between treatment and 
muscle group (1 month p = 0.8203, 3 month p = 0.9449, 5 month p = 0.8125).  
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IV. Figures 
 
Figure 2.1. Vector construct design and miR-206 specificity. (A) Anti-miR-206 
construct design. Four tandem repeats of the exact antisense sequence were placed in 
the 3’ UTR of a GFP expression marker driven by a CMV promoter. The sequence was 
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followed by a poly-A signal and flanked by ITRs on either side for packaging into the 
AAV capsid. (B) Anti-miR-206 specificity for miR-206 was tested in vitro. CMV-GFP-
anti-miR-206, CMV-pre-miR-206 and CMV-pre-miR-124 sequences were packaged into 
the AAV2 capsid and used to transduce HEK293 cells. AAV2-CMV-GFP-anti-miR-206 
transduction alone (first row, MOI: 106 vg/cell) elicited high GFP expression, which was 
reduced by co-transduction with miR-206 precursor (second row, 1x MOI: 106 vg/cell 
and third row, 2x MOI: 2 x 106 vg/cell). The presence of miR-124 had no effect on GFP 
expression (fourth row). Magnification: 10x, scale bar = 300 μm. 
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Figure 2.2. Motor function improvements with anti-miR-206 treatment. Rotarod 
running time was measured in PBS, control vector and AAV9-anti-miR-206 treated mdx 
mice at (A) 1, (B) 3 and (C) 5 months post-treatment. Significant improvements were 
observed with treatment at 1 and 5 months (**p = 0.0105 and **p = 0.0044 for PBS vs. 
treated and **p = 0.0038 for sham vector vs. treated, n = 6). Grip strength was also 
assessed at baseline and until 5 months post-treatment (D). Significant increases in 
strength were observed in anti-miR-206 treated mice versus the untreated group at 4 
months (*p = 0.0372 and *p = 0.0227 for PBS and sham vector vs. treated, respectively) 
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and 5 months (*p = 0.0376 and *p = 0.0455 for PBS and sham vector vs. treated, 
respectively) post-treatment. No discernable differences were observed in treadmill 
running distance at (E) 1 month, (F) 3 months, or (G) 5 months post-treatment. Bars 
represent mean with SEM. 
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Figure 2.3. MicroRNA-206 levels in muscle. MicroRNA-206 levels were measured in the diaphragm from untreated and 
treated mdx mice as well as age-matched WT mice at (A) 1 month, (B) 3 months and (C) 5 months post-treatment. (A) At 
1 month, miR-206 was significantly upregulated in untreated mdx muscle compared to WT (**p = 0.0055, n = 6). 
MicroRNA-206 levels appeared to decrease with treatment with considerable variation. (B) MicroRNA-206 was 
upregulated in dystrophic muscle and treated muscle compared to WT at 3 months (***p < 0.0001, n = 6). MicroRNA-206 
significantly decreased with AAV9-anti-miR-206 treatment compared to the untreated group (*p = 0.0341). (C) At 5 
months, treatment had no effect on miR-206 levels. In both mdx groups, miR-206 was again significantly more abundant 
than the WT (***p < 0.0001, n = 6). Bars represent mean with SEM. 
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Figure 2.4. VEGF transcript levels in muscle. VEGF mRNA in diaphragm from untreated and treated mdx mice as well 
as age-matched WT mice was quantified at (A) 1 month, (B) 3 months and (C) 5 months post-treatment. (A) At 1 month, 
dystrophic muscle contained significantly less VEGF mRNA than the WT (*p = 0.0198, n = 6). With treatment, transcript 
levels slightly increased. (B) Two months later, VEGF mRNA was significantly upregulated in treated muscle compared to 
the untreated (**p = 0.0026, n = 6). (C) Again, significantly lower transcript levels were observed in untreated mdx muscle 
vs. WT (***p < 0.0001, n = 6). While treated muscle contained a greater quantity of VEGF transcripts than untreated, this 
result was not statistically significant (p = 0.0683, n = 6). Bars represent mean with SEM. 
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Figure 2.5. VEGFA expression in muscle. VEGFA protein levels were examined by 
Western blot at 1 month post-treatment in tibialis anterior muscle samples. 
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Figure 2.6. Increased capillary density in treated mdx muscle. Capillaries were quantified in diaphragm muscle from 
untreated and treated mdx mice as well as age-matched WT mice at (A) 1, (B) 3 and (C) 5 months post-treatment. (A) At 
1 month, the number of capillaries per fiber was significantly lower in mdx muscle compared to WT (*p = 0.0495, n = 6). 
Capillary density was similar in treated muscle. (B) At 3 months, the number of capillaries per fiber in dystrophic muscle 
was again significantly lower than in the WT (***p = 0.0008, n = 6). A distinct increase was found after treatment (mdx vs. 
mdx+amiR ***p < 0.0001, n = 6). A significant increase was also observed between WT and treated mdx muscle (*p = 
0.0244, n = 6). (C) At 5 months, capillary density was decreased in dystrophic muscle compared to WT (**p = 0.0043, n = 
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6). On the other hand, treatment significantly increased the number of capillaries per fiber compared to untreated mdx (*p 
= 0.0258). Bars represent mean with SEM.
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Figure 2.7. Reduced vessel permeability in treated muscle. Miles assay to 
determine Evans blue dye content (ng/mg tissue) was performed with muscle from 
untreated and treated mdx mice as well as age-matched WT mice at (A) 1 month, (B) 3 
months and (C) 5 months post-treatment. (A) At 1 month, a significant increase in dye 
permeation in dystrophic muscle was observed compared to WT (*p = 0.0349, n = 6). 
(B) At 3 months, mdx dye content was again statistically greater than WT (**p = 0.0094, 
n = 6). Dye levels were significantly reduced with treatment (*p = 0.0278, n = 6). (C) At 5 
months, dye content was significantly greater in mdx muscle than WT (*p = 0.0220, n = 
6). With treatment, mdx muscle contained considerably less dye (#, *p = 0.0351, n = 6). 
Bars represent mean with SEM. 
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V. Discussion 
 In this chapter, I examined the role of microRNA-206 in muscle vascularization 
and if downregulation of miR-206 would confer therapeutic benefit by allowing 
expression of VEGFA. I show for the first time that miR-206 can be bound by an 
antisense construct, “anti-miR-206,” which acts as a decoy target transcript or 
microRNA “sponge.” Excess amounts of miR-206 in vitro completely eliminated 
expression of a GFP reporter gene containing the antisense sequence in its 3’ UTR. 
MicroRNA sponges have been used to competitively inhibit small RNAs in mammalian 
cells to derepress target gene expression (Ebert, Neilson et al. 2007). This is usually 
accomplished in vivo by direct administration of complementary oligonucleotides, or 
antagomirs, which tend to be 2’-O-methyl, phosphorothioate or cholesterol-modified. 
Similar to exon skipping, these antagomirs only offer a transient effect and suffer from 
poor uptake unless a large dose is applied. To overcome this, microRNA inhibitory 
constructs have been packaged into viral vectors to enable long-term suppression 
(Haraguchi, Ozaki et al. 2009). Stable miR suppression has been demonstrated in vivo 
in bone marrow reconstitution and cancer xenograft models (Ebert and Sharp 2010). To 
accomplish this, I packaged the anti-miR-206 construct into an AAV9 vector, which 
displays superior muscle tropism and stable gene transfer for up to 2 years (Kornegay, 
Li et al. 2010, Qiao, Koo et al. 2011). Administration of the completed vector effectively 
reduced miR-206 levels in mdx mice. However, miR-206 inhibition in the diaphragm was 
short-lived and was not observed at 5 months post-treatment. This could be attributed to 
severe pathology and continuous muscle death, causing the loss of transduced tissue.   
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 Interestingly, AAV9-anti-miR-206 treatment provided therapeutic benefit to mdx 
mice. Rotarod testing revealed significant improvements in balance and motor 
coordination with treatment. Additionally, grip strength was maintained in mice treated 
with anti-miR-206 over the experimental period. It is possible that the construct is still 
present in the limbs of mdx mice, which display milder dystrophic symptoms and muscle 
degeneration compared to the diaphragm (Stedman, Sweeney et al. 1991). Thus, 
treatment impeded eventual motor decline in the mdx. 
Treadmill running had two purposes in this study: to assess motor function and 
exacerbate muscle damage for treatment comparison (Grounds, Radley et al. 2008). 
While no significant differences in run distance were observed, forced eccentric 
contraction may have amplified functional decline observed in mdx mice during rotarod 
and grip force testing. Furthermore, respiratory or cardiac impairments do not develop in 
the mdx mouse until 6 and 16 months of age, respectively. It is possible that these 
deficiencies are not severe enough to affect motor performance during the experimental 
period. Another study noted that changes in perfusion after induced ischemia were 
observed only in aged mdx mice (12 months), suggesting that vascular impairments 
may not develop until later (Latroche, Matot et al. 2015). Discrepancies in testing 
protocols and the motivation of the mice to run may also contribute to the these results. 
 Finally, target expression and muscle vascularization were evaluated to 
determine the therapeutic mechanism of miR-206 downregulation. VEGFA transcript 
levels in muscle significantly increased with anti-miR-206 treatment and protein levels of 
the ubiquitous isoform were elevated accordingly. Thus, treatment with this microRNA 
sponge relieved target gene inhibition. In zebrafish, angiogenesis was observed after 
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inhibition of miR-206, which permitted VEGFA activity (Stahlhut, Suarez et al. 2012, Lin, 
Lee et al. 2013). The angiogenic properties of VEGFA have been used in DMD 
treatments to ameliorate functional ischemia, which significantly increased capillary 
density in muscle as well as forelimb strength after intramuscular injection (Messina, 
Mazzeo et al. 2007). Transgenic mdx/Flt-1 knockout mice, which have increased ratios 
of capillaries to muscle fibers, have also shown improvements in muscle histology, 
blood flow and force production (Verma, Asakura et al. 2010). Similarly, miR-206 
reduction significantly increased capillary density in dystrophic muscle. Due to concerns 
regarding vascular permeability with systemic VEGFA expression, vessel integrity was 
tested. Abnormal vasoregulation in dystrophic muscle has also been linked to 
diminished vessel integrity caused by dystrophin loss in smooth muscle cells. 
Transgenic mice expressing dystrophin solely in vascular smooth muscle cells exhibited 
normal hemodynamic responses after muscle contraction. While no differences in basal 
blood flow were seen between these mice, mdx and control mice, vascular dystrophin 
expression produced an intermediate muscle pathology. These finding suggest that 
vessel defects can contribute to the severity of dystrophic symptoms (Ito, Kimura et al. 
2006). Miles assay revealed that dye extravasation in different muscle groups was 
significantly lowered with treatment and comparable to WT levels, which may be an 
indication of normalization of the vessel lining and the dystrophic phenotype. Alterations 
in microvessel endothelial cells of the blood-brain barrier have been observed in mdx 
(Nico, Frigeri et al. 2003). The open tight junctions of the microvessels caused abnormal 
permeability of the BBB, which may be associated with neurological dysfunction 
observed in DMD patients. Although the Miles assay has been typically employed in 
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DMD studies to look at muscle membrane integrity, mice are usually subjected to 
additional exercise and sacrificed 24 hours later. Mice were sacrificed 30 minutes after 
dye administration, which would allow transient circulation and only measure 
extravasation from the vessels. 
 Although increases in VEGFA expression were found, the question of its role in 
motor function improvements still remains. Prior to experimentation, it was thought that 
vascular improvements would influence endurance due to enhanced blood flow and 
aerobic capacity. In a study with muscle-specific VEGFA-deficient mice, significant 
decreases in capillary density and treadmill endurance were observed (Olfert, Howlett et 
al. 2009). However, the previously mentioned study involving AAV-mediated VEGFA 
delivery showed increased capillary density, but did not evaluate endurance nor blood 
flow (Messina, Mazzeo et al. 2007). Vascular smooth muscle and endothelial cells in 
mdx mice are still dystrophin-deficient and unable to recruit nNOS to induce proper 
vasoregulation in response to exercise (Loufrani, Levy et al. 2002, Ito, Kimura et al. 
2006). Since our treatment does not target nNOS, the lack of blood flow regulation to 
affect performance during long bouts of vigorous exercise is understandable. On the 
other hand, defects in microvascular stress have been observed in mdx mice. This can 
be attributed to reduced endothelial diameter, which cannot withstand or mediate 
normal blood flow resistance (Loufrani, Levy et al. 2002). Increases in capillary density 
and integrity may address such issues with normal vessel stress and localized blood 
flow to the muscle to decrease pathology, producing the observed motor function 
improvements. It is also possible that treatment improves expression of B-utrophin, 
which localizes to the vessel endothelium (Weir, Burton et al. 2002). While utrophin 
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cannot sequester nNOS, it may substitute for dystrophin’s structural role to improve 
vessel integrity similar to muscle (see Chapter III). Our observations of reduced Evans 
blue dye permeation with treatment support some degree of vessel integrity correction, 
which could aid in normalizing vessel stress and blood flow. Pharmacological agents 
work directly on the smooth muscle cells to induce vasodilation and improve exercise-
related muscle aerobic capacity (Khurana and Davies 2003, Nelson, Rader et al. 2014). 
In contrast to gene therapies that improve vessel density and function, the effect of 
these treatments is temporary and may not address the progression of muscle 
pathology long-term. Overall, these results support a therapeutic role for miR-206 
downregulation via VEGFA-induced muscle vascularization. 
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CHAPTER 3: DOWNREGULATION OF MICRORNA-206 IMPROVES MUSCLE 
PATHOLOGY IN MDX MICE 
I. Introduction 
 Due to its similarity with dystrophin, several therapeutic strategies have aimed to 
provide or upregulate endogenous utrophin in dystrophic muscle. Utrophin is 
comparable in size to dystrophin (395 kDa) and its primary structure bears resemblance 
to dystrophin, especially at the NH2 and COOH terminal domains (Blake, Weir et al. 
2002). Overexpression of utrophin at the sarcolemma of transgenic mdx muscle 
prevented development of dystrophic symptoms and maintained normal muscle function 
(Deconinck, Tinsley et al. 1997, Tinsley, Deconinck et al. 1998). In addition, AAV 
delivery of a micro-utrophin protein ameliorated disease pathology, normalizing muscle 
fiber morphology and force generation (Odom, Gregorevic et al. 2008). Increasing 
utrophin levels also promoted structural integrity of the myofiber and increased 
resistance to contraction-induced damage. The findings from these studies underscore 
the compensatory role and therapeutic value of utrophin. 
Studies with mdx mice and DMD patients have found that utrophin is upregulated 
in dystrophic muscle (Khurana and Davies 2003). While utrophin levels may explain the 
milder phenotype of mdx, they are not sufficient for improving muscle pathology in DMD 
patients (Deconinck, Rafael et al. 1997). Treatment with pharmacological agents, such 
as SMTC110, which work to increase endogenous utrophin expression have benefitted 
disease muscle (Tinsley, Fairclough et al. 2011, Tinsley, Robinson et al. 2014). 
Furthermore, it is believed that increasing endogenous utrophin avoids issues with 
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dystrophin-specific T cell targeting associated with gene replacement strategies. In one 
study, viral-mediated gene transfer of utrophin persisted longer and elicited a weaker 
immune response compared to dystrophin in immunocompetent mice (Ebihara, 
Guibinga et al. 2000). 
MicroRNA-206 is overexpressed in DMD, but its role in disease pathology has 
not been defined. Utrophin is a known target of miR-206 and its expression is known to 
be post-transcriptionally regulated (McCarthy 2008). Overexpression of miR-206 in 
muscle cell culture had a strong inhibitory effect on utrophin levels, suggesting direct 
regulation of utrophin via its 3’ UTR (Rosenberg, Georges et al. 2006). Similarly, high 
levels of miR-206 may contribute to insufficient utrophin expression observed in 
dystrophic muscle. Reducing miR-206 in the muscle may relieve its inhibitory effect, 
increasing endogenous expression of therapeutic booster genes, such as utrophin, and 
improving dystrophic pathology. To this end, I investigated whether miR-206 influences 
muscle pathology and expression of one of its target, utrophin. First, I measured 
utrophin expression, looking at both the transcript and protein level to determine if miR-
206 negatively regulates utrophin. Second, I examined general muscle pathology by 
H&E staining in response to treatment. Third, I assessed the effect of treatment on 
related dystrophic symptoms, including fibrosis, fiber regeneration, serum CK, myofiber 
size and muscle mass. Lastly, I looked at vector persistence in the muscle to assess 
long-term efficacy. Findings from these studies could help to clarify the role of miR-206 
in muscle pathology and define a new strategy for treating DMD.
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II. Materials and methods 
Utrophin transcript quantification 
Total RNA was extracted from diaphragm muscle using TRIzol reagent according 
to the manufacturer’s instructions (Thermo Fisher Scientific) and stored at -80°C until 
further use. A cDNA template for microRNAs was created using the miRNA 1st-Strand 
cDNA Synthesis Kit (Agilent Technologies). The resulting template was diluted 1:5 for 
quantitative PCR (qPCR). Reactions were set up using PowerUp SYBR Green Master 
Mix (Thermo Fisher Scientific) according to the manufacturer’s protocol and run in an 
Applied Biosystems 7300 Thermocycler. Utrophin expression was quantified relative to 
ubiquitous beta-actin. The primers used were as follows: utrophin (forward: 5’-
CACTGGCAGGTGAAGGATGT-3’, reverse: 5’-CTTGACTGTAGGGCCTGGTG-3’) and 
beta-actin (forward: 5’-ATCACTATTGGCAACGAGCG-3’ and reverse: 5’-
ACTCATCGTACTCCTGCTT-3’). Expression was depicted as fold-change over control. 
Western blot 
Gastrocnemius (GAS) muscle was homogenized in cold dystrophin lysis buffer 
(2% SDS, 6.25 mM Tris pH 8.8, 2% glycerol, PMSF, 50 mM DTT, 0.005% BPB) using a 
tissue homogenizer (Tekmar Ultrasonic Processor model TM130). Protein concentration 
was determined by BCA assay. For Western blotting, 50 μg (for utrophin detection) and 
15 μg (for GAPDH detection) protein from each sample was prepared in 2X dystrophin 
loading buffer (5% SDS, 0.75 M Tris pH 8.8, 2% glycerol, 100 mM DTT, 1% BPB) and 
heated at 95°C for 5 minutes. Proteins were separated by SDS-PAGE and wet 
transferred onto a PVDF membrane using the Bio-rad Mini-PROTEAN II system. 
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Membranes were blocked in 5% milk in 1% TBS-Tween 20 (TBS-T) for 1 hour and 
incubated with either goat polyclonal antibody against utrophin (Santa Cruz 
Biotechnology, #sc-7459, 1:1000) or rabbit polyclonal antibody against GAPDH (Sigma-
Aldrich, cat. # G9545, 1:10,000) diluted in 3% bovine serum albumin (BSA) in 1% TBS-
T overnight at 4°C. Membranes were washed 3 times for 10 minutes in 1% TBS-T and 
then incubated with anti-goat or anti-rabbit IgG conjugated to horseradish peroxidase 
(Sigma, A5420, 1:5,000 for utrophin and Sigma-Aldrich, A0545, 1:10,000 for GAPDH) in 
5% milk. Blots were developed using the Western Lightening ECL reagent (Pierce) and 
visualized using the FluorChem M system. 
Utrophin immunostaining 
 GAS muscle samples were processed into 10 μm cryosections and mounted on 
glass slides. At room temperature, slides were blocked in 10% horse serum for 1 hour. 
Utrophin was immunostained with a goat utrophin antibody (Santa Cruz Biotechnology, 
#sc-7459, 1:100) in 1% horse serum in PBS overnight at 4°C and then washed with 
0.5% PBS-T 3 times for 5 minutes each. Anti-goat IgG conjugated to Cy3 dye (1:500, 
Jackson ImmunoResearch Laboratories, Inc.) was diluted in 1% horse serum and used 
to incubate slides for 1 hour. Slides were washed with 0.5% PBS-T 3 times for 5 
minutes each and mounted with aqueous mounting media (Gel/Mount, Biomeda). Slides 
were visualized using a Zeiss Axiovert 200M Confocal Microscope and images were 
taken using an AxioCam MRm camera. 
Hematoxylin & eosin (H&E) staining 
 Frozen muscle samples were cryosectioned 10 μm in thickness and placed on 
glass slides. Slides were fixed in 3% acetic acid (in 95% ethanol) and washed with tap 
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water. They were then stained in Gill’s hematoxylin solution (#24244, Polysciences, 
Inc.) for 30 minutes (min) to visualize cell nuclei. Slides were washed in running tap 
water then differentiated in 1% acid alcohol (hydrochloric acid in 70% ethanol) for about 
30 seconds (sec). After washing in tap water, tissue was blued in 0.2% ammonia water 
for 30 sec to 1 min. Slides were then washed again and counterstained with eosin for 
about 5 sec to visualize eosinophilic structures (i.e. sarcoplasm). Serial dehydration was 
performed in 70%, 85%, 95% and 100% ethanol. Slides were then cleared in xylene 3 
times for at least 5 min overall and mounted with Permount (Fisher). Images were 
acquired using a Nikon Eclipse TE300 microscope (Nikon USA) and a SPOT RT Slider 
camera (Diagnostic Instruments, Inc.). H&E images were used for centrally located 
nuclei quantification and analyzed in ImageJ using the Cell Counter function. 
Collagen staining 
 To examine the level of fibrosis in muscle samples, two methods of collagen 
staining were performed. To visualize areas containing collagenic compounds, Masson 
trichrome staining was performed using solutions from a kit (IMEB Inc.). Slides were 
made by cryosectioning frozen muscle samples, which were then fixed in Bouin’s 
solution for 15 to 20 min. After rinsing in water, sections were stained in hematoxylin 
solution for 10 min to visualize nuclei. After another rinse, sections were placed in 
Biebrich’s scarlet acid fuschin solution for 15 min to stain the sarcoplasm then rinsed 
again. Slides were placed in Phosphotungstic/Phosphomolybdic acid solution for 15 
min, then directly transferred into aniline blue stain solution to stain collagenic areas. 
After rinsing, slides were serially dehydrated as mentioned above (Hematoxylin & eosin 
(H&E) staining). Slides were then cleared in two changes of xylene for at least 5 min in 
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total. Slides were mounted with Permount. Collagen fibers and muscle were stained 
with Sirius red and fast green, respectively. Frozen sections were allowed to reach room 
temperature, then fixed in pre-warmed Bouin’s solution for 15 to 20 min. Slides were 
washed in lukewarm running tap water until yellow color faded. They were then stained 
in 0.1% Fast green (in water) for 10 to 15 min and washed briefly in tap water. Slides 
were then placed in 1% acetic acid solution for 2 minutes and then directly into 0.1% 
Sirius red stain (in water) for 30 minutes. Slides were dehydrated in 100% ethanol for 2 
to 3 minutes twice and xylene cleared for at least 5 min. Finally, slides were mounted 
with Permount. Images were acquired using a Nikon Eclipse TE300 microscope (Nikon 
USA) and a SPOT RT Slider camera (Diagnostic Instruments, Inc.). The percentage of 
fibrosis was calculated with Sirius red/fast green images using ImageJ software and the 
Threshold_Colour plugin. 
Hydroxyproline quantification 
 Hydroxyproline, a non-proteinogenic amino acid, is particularly abundant in 
collagen, making up ~13.5% of the total composition. Hydroxyproline content was 
determined using the method described by Carlson (2009). Diaphragm samples were 
extracted and hydrolyzed in 5 M HCl in a 108°C dry bath overnight. After bringing 
samples to room temperature, 50 μg of sample was diluted in 2.25 ml ddH2O and then 
neutralized with 0.1 N and 0.8 N KOH solutions. A hydroxyproline standard was also 
made at this time. Sodium borate buffer (0.1 M, pH 8.7) was added and then the mixture 
was oxidized with 2 ml of 0.2 M chloramine-T solution. After a 25 min incubation period, 
1.2 ml of 3.6 M sodium thiosulfate was added to stop the oxidation reaction and 
vortexed briefly. Next, 2.5 ml toluene and 1.5 g KCl were added. The samples were 
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inverted slowly for 5 min on a test tube inverter then centrifuged at 300 x g for 1 minute. 
The toluene phase containing impurities was removed and the remaining aqueous layer 
was heated at 100°C in a dry bath for 30 min to convert the oxidized hydroxyproline 
(pyrrole-2-carboxylic acid) to pyrrole. After cooling to room temperature, another 2.5 ml 
of toluene was added and mixed with the aqueous solution to extract the pyrrole. After 
another round of centrifugation, 1.5 ml of the organic phase was mixed with 0.6 ml 
Erlich’s reagent and developed for 30 min at room temperature. Sample and 
hydroxyproline standard absorbances were read at 560 nm. Hydroxyproline content was 
expressed as μg per mg muscle. 
Fiber diameter 
 Cryosections of diaphragm muscle 10 μm thick from WT, mdx and treated mdx 
were made. At room temperature, slides were washed in PBS for 10 minutes then 
blocked in 10% horse serum for 1 hour. The muscle basal lamina was immunostained 
with a rat anti-laminin α2 antibody (Sigma-Aldrich, L0663, 1:500) in 1% horse serum in 
PBS for 1 hour and washed with 0.5% PBS-T 3 times for 5 minutes each. Anti-rat IgG 
conjugated to Alexa Fluor 488 dye (Molecular Probes, #A21470) was diluted in 1% 
horse serum and used to incubate slides for 1 hour. Slides were washed with 0.5% 
PBS-T 3 times for 5 minutes each and mounted with Gel/Mount. Slides were visualized 
using a Zeiss Axiovert 200M Confocal Microscope and images were taken using an 
AxioCam MRm camera. Images were analyzed using ImageJ software and the Analyze 
Particles function to measure area. Diameter was then calculated in Microsoft Excel and 
graphed in GraphPad Prism 5.0. 
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Serum creatine kinase 
 Muscle contains high levels of creatine kinase (CK) and if damaged, will leak CK 
into the blood. Measuring serum CK activity thus serves as an overall assessment of 
muscle injury. Whole blood samples were collected with BD Microtainer Serum 
Separator tubes at the time of sacrifice from the carotid artery. Tubes were spun at 
10,000 rpm in a 4°C microcentrifuge for 10 min to separate serum, which was frozen at 
-20°C for later use. Creatine kinase reagent (Pointe Scientific) was used to catalyze the 
formation of NADH formation. The reaction rate of NADH production was measured at 
340 nm. The serum CK in the samples catalyzes the formation of creatine and ATP 
from ADP and creatine phosphate. Hexokinase then catalyzes the production of 
glucose-6-phosphate and ADP from ATP and glucose. Finally, glucose-6-phosphate 
and NAD+ are formed into 6-phopshogluconate, NADH and H+ through glucose-6-
phosphate dehydrogenase. 
Body weight and muscle mass 
Body weight was measured every 2 weeks after grip force testing. Muscle mass 
for quadriceps, hamstring, gastrocnemius, tibialis anterior and tricep muscles was 
measured upon dissection. 
Vector persistence 
 DNA was extracted from diaphragm and gastrocnemius muscle samples using 
the DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer’s protocols. 
Absolute qPCR was performed to determine vector genome copies per cell. Two 
standards were created by serial dilution of the CMV-1/2gfp-anti-miR-206 vector 
plasmid and a previously generated plasmid containing a single copy of the mouse 
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glucagon gene. Reactions were set up using the GoTaq Probe qPCR Master Mix 
(Promega) according to the manufacturer’s protocol and run in an Applied Biosystems 
7300 Thermocycler. Vector genomes per cell were calculated by dividing CMV copies 
by half of the total glucagon copies, since one diploid nucleus contains two copies of the 
glucagon gene. The primers used were as follows: CMV promoter (forward: 5’-
GTATGTTCCCATAGTAACGCCAATAG-3’, reverse: 5’-
GGCGTACTTGGCATATGATACACT-3’, probe: FAM-TCAATGGGTGGAGTATTTA) 
and glucagon (forward: 5’-AAGGGACCTTTACCAGTGATGTG -3’ and reverse: 5’-
ACTTACTCTCGCCTTCCTCGG-3’, probe: FAM-CAGCAAAGGAATTCA). 
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III. Results 
Utrophin expression 
 Utrophin transcript levels were examined using relative qPCR in WT, mdx and 
treated mdx diaphragm (Fig. 1). At 1 month, utrophin expression in dystrophic muscle 
was significantly upregulated, nearing 3-fold, compared to WT (Fig. 1A, WT vs. mdx **p 
= 0.0016, WT vs. treated mdx ***p = 0.0001, n = 6), with no marked difference between 
the two mdx groups. Dystrophic muscle transcript levels were again greater (~2-fold) 
than the WT (***p<0.0001, n = 6) at 3 months (Fig. 1B). At the same time, a significant 
~2-fold increase in utrophin transcripts was observed with treatment compared to the 
untreated group (***p = 0.0001, n = 6). Transcript levels in the treated group were ~4-
fold greater than in WT (***p<0.0001, n = 6). A similar pattern was found two months 
later; however, the difference between the untreated groups was not statistically 
significant (Fig. 1 C, p = 0.2059, n = 6). Still, dystrophic muscle contained significantly 
greater levels of utrophin mRNA than the WT (WT vs. mdx *p = 0.0389, WT vs. treated 
mdx **p = 0.0051). Western blot was performed to examine utrophin expression at the 
protein level in the gastrocnemius muscle (Fig. 2). Due to cross-reactivity with 
dystrophin in WT samples, only mdx groups were compared.  After incubation with a 
utrophin-specific antibody, a band was observed at ~400 kDa, which corresponds in 
size to utrophin. A noticeable increase in expression was observed with treatment at 3 
months, which mirrors increases in transcript levels. 
 Immunofluorescent staining was performed to determine utrophin localization in 
gastrocnemius muscle (Fig. 3). WT and untreated mdx displayed sparse and punctate 
utrophin expression, which can be attributed to neuromuscular junction (NMJ) staining. 
  69 
In anti-miR-206 treated muscle, NMJ staining was stronger and more abundant than in 
WT or untreated muscle. A distinct staining pattern lining the edges of the muscle fiber 
(highlighted in zoomed images) was also observed, likely due to utrophin expression at 
the sarcolemma. 
Muscle pathology is normalized with treatment 
 Muscle pathology was examined by H&E staining in diaphragm and hamstring 
muscle over the course of 5 months (Fig. 4). Normal muscle is characterized by fibers 
that are organized, uniform in size and with nuclei located at the periphery. WT muscle 
generally appeared normal within the given time period. In contrast, dystrophic muscle 
showed signs of degeneration (irregularly shaped fibers that are pale pink with 
fragmented sarcoplasm or swelled, hypercontracted fibers with dark pink staining) and 
regeneration (smaller fibers with centrally located nuclei) with mononuclear cell 
infiltration (small basophilic cells without cytoplasm). Muscle damage in the mdx 
diaphragm was markedly severe compared to the hindlimb. At 3 months, regenerating 
fibers in untreated mdx appeared to be more abundant than at 1 or 5 months in both 
diaphragm and hamstring. In treated mdx, dystrinopathy was less serious. Treated 
diaphragm was more organized and myofibers were relatively more uniform in size and 
shape than in the untreated sample. In addition, there appeared to be less inflammatory 
cell infiltration. Over time, overall myofiber area within the mdx diaphragm appeared to 
decrease and seemingly replaced by fibrotic tissue (unstained spacing between fibers). 
Decreased fibrosis in treated mdx mice 
  In dystrophic muscle, functional muscle mass is replaced by fibrotic collagen. 
Collagen deposition is particularly pronounced in the mdx diaphragm, which has been 
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shown to contribute to respiratory impairments that develop with age. Two methods of 
histological staining were used to assess fibrosis qualitatively.  Masson trichrome 
staining was performed at 3 and 5 months post-treatment (Fig. 5A and 5B, respectively) 
to detect collagenic compounds. No collagen deposition was observed in the WT 
diaphragm at either timepoint. On the other hand, mdx diaphragm was severely fibrotic, 
with collagen occupying close to half of the muscle area. Treated mdx diaphragm was 
also fibrotic, yet to a lesser degree and in a more organized fashion compared to 
untreated muscle. These results were paralleled with picrosirius red/fast green staining, 
which is used to stain collagen fibers versus collagen constituents. In addition to 
diaphragm muscle (Fig. 6A and 6C), hamstring muscle was also stained to examine 
hindlimb fibrosis (Fig. 6B and 6D). Again, no fibrosis was observed in WT muscle at 
either timepoint. In dystrophic diaphragm, there was substantial collagen deposition at 
both times. In contrast, collagen staining was more diffuse in treated diaphragm, which 
suggests that fewer mature collagen fibers are present and progression of fibroses is 
less advanced than in the untreated sample. In the hamstring, differences in collagen 
deposition were less distinguishable between groups, particularly at the 5 month 
timepoint. Picrosirius red staining was quantified and revealed a mean of 34.45 + 2.081 
and 27.67 + 5.711 at 3 and 5 months, respectively, in the dystrophic diaphragm (Fig. 7A 
and 7C). A significant reduction of fibrosis in both the mdx diaphragm (mean = 22.51 + 
3.274) and hamstring muscle (Fig. 7B, mean = 18.64 + 1.673) with treatment at 3 
months post-treatment (**p = 0.0043 and *p = 0.0279, respectively). At 5 months, 
diaphragm collagen deposition was also decreased in the treated vs. untreated group 
(mean = 21.56 + 3.949); however, this was not statistically significant (p=0.3919). At the 
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same time, there was no apparent difference in hamstring collagen staining across all 
groups (Fig. 7D, WT vs. mdx p=0.6045, WT vs. treated p = 0.615, mdx vs. treated p = 
0.8562). 
 Hydroxyproline, a major component of collagen, was also quantified in order to 
evaluate fibrosis in the muscle overall (Fig. 8). Consistent with the staining results, 
hydroxyproline content was greater in mdx diaphragm (mean = 5.967 + 1.407 μg/mg) 
than in WT (mean = 0.5724 + 0.2498 μg/ml, Fig. 8A). Treated diaphragm also contained 
less hydroxyproline (mean = 4.551 + 1.008 μg/mg) compared to the untreated group at 
3 and 5 months post-treatment. Hydroxyproline content increased in all groups at 5 
months yet rose most drastically in untreated mdx (untreated mean = 13.68 + 5.062 
μg/mg and treated mean = 7.461 + 1.546 μg/mg). At 3 months, hamstring muscle 
hydroxyproline values displayed a similar pattern to staining results, with an increase in 
mdx muscle (Fig. 8B, mean = 5.406 + 1.413 μg/mg) and a decrease with anti-miR-206 
treatment (mean = 4.410 + 1.011 μg/mg). Hydroxyproline assay results for hamstring at 
5 months were inconclusive and not shown. 
Normalization of fiber diameter 
 Immature fibers, which are smaller in diameter than mature fibers, are more 
abundant in dystrophic muscle due to active degeneration and regeneration. Fiber 
diameter was calculated in WT, mdx and treated mdx gastrocnemius muscle to 
determine fiber stability at 1, 3 and 5 months post-treatment (Fig. 9). The majority of WT 
fibers ranged between 45 and 75 μm, with a peak at 60 μm, which was consistent at all 
timepoints. However, the percentages of different fiber diameters within this range 
became more evenly distributed with increasing age and a less prominent peak at 60 
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μm was observed by 5 months. Muscle fibers in the untreated group were concentrated 
in the lower size range, with a peak at 10 μm and a gradual decline with increasing 
diameter.  After treatment, mdx fiber distribution still peaked at 10 μm, but appeared to 
shift slightly to larger diameters. Unlike WT muscle, there were no apparent changes in 
fiber size distribution in either mdx groups with age. Fiber diameter in the diaphragm 
was also examined and exhibited a similar pattern to the gastrocnemius muscle (results 
not shown). 
Centronucleation in dystrophic muscle 
 Newly regenerated fibers are recognized by their centrally located nuclei, or 
centronucleation, and are used as another indicator of fiber instability. Muscle fibers 
containing centrally located nuclei were quantified in WT, mdx and treated mdx 
diaphragm muscle at 3 and 5 months post-treatment (Fig. 10A and 10B). 
Centronucleation was not observed in WT muscle at either timepoint. In contrast, a 
large percentage of mdx fibers were centrally nucleated (33.20 + 1.984% and 29.34 + 
3.285%, at 3 and 5 months, respectively). A significant decrease was observed with 
treatment at 3 months (mean = 24.63 + 1.949%, **p=0.0065, n = 6). Centronucleation 
also markedly decreased with anti-miR-206 treatment at 5 months, yet this result was 
not statistically significant (mean = 21.46 + 1.671%, p = 0.0698, n = 6). Slightly less 
centronucleation was observed at 5 months compared to 3 months post-treatment for 
both untreated and treated mdx. 
Reduction of serum muscle creatine kinase in anti-miR-206 treated mice 
Striated muscle contains high levels of creatine kinase (CK), which is released 
into the serum in response to damage. Serum CK was measured in WT, mdx and 
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treated mdx to evaluate overall muscle damage (Fig. 11). At the 3 month timepoint, WT 
serum contained an average of 240.6 + 74.75 u/L CK, which decreased to 176.3 + 
22.46 u/L two months later. Compared to WT, mdx serum contained much greater 
levels of CK (up to 17,083 u/L, **p = 0.0224, and 12,531 u/L, *p = 0.0365, respectively) 
at 3 months and 5 months. Mean CK values for mdx serum were 8,512 + 2535 u/L and 
6,134 + 1,927 u/L at 3 and 5 months, respectively. Serum CK values in mdx varied 
greatly, with a range of  ~15,000 u/L at 3 months and ~10,000 u/L at 5 months. In 
response to anti-miR-206 treatment, CK values were reduced, with a mean of 4,412 + 
1,123 u/L and 5,295 + 1148 u/L at 3 and 5 months post-treatment. However, compared 
to untreated mdx, this result was not significant (p = 0.1896 and p = 0.7214 at 3 and 5 
months, respectively). Still, treated mdx exhibited a much smaller range of CK values 
versus the untreated group, with a range of ~6,000 u/L and ~7,000 u/L at 3 and 5 
months, respectively. Compared to WT, treated mdx levels were nonetheless 
significantly greater at both timepoints (*p = 0.0139 and *p=0.0112 for 3 and 5 months, 
respectively).  
Bodyweight & muscle mass 
 Bodyweight was measured in untreated and treated mice between 1 and 5 
months post-treatment (Fig. 12). While bodyweight increased steadily in untreated and 
treated mice, no major differences in weight were found between the two groups. 
Similarly, no notable changes were observed in muscle mass with treatment (Fig. 13).  
Hamstring mass very slightly increased between 1 and 5 months in the treated group. 
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Vector persistence 
 To determine if the AAV vector genome remained in the muscle over time, 
absolute qPCR was performed with diaphragm and gastrocnemius samples from AAV9-
anti-miR-206 treated mice (Fig. 14). At one month, ~0.3 vector genomes (vg) were 
detected per cell in the gastrocnemius muscle, which stayed constant two months later. 
The amount of vector genomes decreased by 5 months to ~0.2 vg/cell. In contrast, 
diaphragm muscle harbored up to 10 vg/cell with an average of 5 vg/cell at 1 month. 
Vector concentration was reduced by about half at 3 months. Finally, vector 
concentration was 0.5 vg/cell at 5 months. Overall, the diaphragm was highly 
transduced yet experienced considerable vector genome loss within the time period 
compared to the gastrocnemius muscle. 
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IV. Figures 
Figure 3.1. Upregulation of utrophin transcripts with treatment. Utrophin mRNA was quantified in diaphragm from 
untreated and treated mdx mice as well as age-matched WT mice at (A) 1, (B) 3 and (C) 5 months post-treatment. (A) 
Utrophin transcript levels were significantly greater at 1 month in both untreated mdx and treated mdx muscle versus WT 
(**p = 0.0016 and ***p = 0.0001, respectively, n = 6). (B) At 3 months, a significant increase in transcripts was again 
observed in mdx and treated mdx compared to WT (***p < 0.0001, n = 6). Utrophin mRNA in treated muscle was 
considerably upregulated compare to untreated muscle (**p = 0.0012, n = 6). (C) Two months later, mdx and treated mdx 
levels were consistently greater than WT (*p = 0.0389 and **p = 0.0051, respectively, n = 6). Treatment increased 
utrophin levels, but this difference was not statistically significant. Bars represent mean with SEM.
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Figure 3.2. Upregulation of utrophin protein with treatment. Utrophin expression 
was examined in the gastrocnemius muscle from untreated and treated mdx mice at 3 
months post-treatment. 
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Figure 3.3. Utrophin localization at the muscle membrane. Immunofluorescent staining was performed in 
gastrocnemius muscle from WT, mdx and treated mdx mice at 3 months. WT and mdx muscle had sparse, punctate 
utrophin staining while utrophin appeared to localize at the muscle membrane in the treated muscle. Bar = 100 μm, 
magnification: 10X. 
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Figure 3.4. Improvement in muscle pathology with AAV9-anti-miR-206 treatment. 
Pathology was observed at 1 month in (A) diaphragm and (B) hamstring muscle. 
Dystrophic pathology was more severe in mdx muscle than in WT or with treatment. 
Staining showed that dystrinopathy became more severe at 3 months in (C) diaphragm 
as well as (D) hamstring. Treatment once again appeared to lessen severity. Finally, 
muscle condition was observed at 5 months in (E) diaphragm and (F) hamstring. Again, 
dystrophic symptoms were worse in the mdx diaphragm than in the WT or untreated. 
Pathology was not as pronounced in the hamstring across all groups. Bar = 300 μm, 
magnification: 10X. 
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Figure 3.5. Decreased collagen deposition with treatment. Masson trichrome 
staining was performed to examine fibrosis in diaphragm at (A) 3 months and (B) 5 
months post-treatment. Collagen deposition is represented in blue and sarcoplasm in 
red. Little to no collagen was found within WT muscle. In contrast, collagen deposition 
was greatly increased in dystrophic muscle. While fibrosis was still observed with 
treatment, it was decreased overall and occupied a smaller area than without treatment. 
Bar = 300 μm, magnification: 10X. 
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Figure 3.6. Reduced fibrosis in treated muscle. Picrosirius red/fast green staining 
was performed to detect collagen fibers at 3 months in (A) diaphragm and (B) hamstring 
and 5 months in (C) diaphragm and (D) hamstring. Collagen fibers are shown in red, 
while sarcoplasm is stained green. Fibrosis was greatly increased in dystrophic 
diaphragm, but more diffuse in the treated sample, suggestive of fewer mature collagen 
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fibers. WT did not show any fibrosis. While an increase in fibrosis was observed in 
dystrophic muscle compared to normal muscle, no discernable changes were seen in 
the hamstring between groups. 
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Figure 3.7. Reduced fibrotic area in treated muscle. Picrosirius red staining was 
quantified at 3 months in (A) diaphragm and (B) hamstring and at 5 months in (C) 
diaphragm and (D) hamstring. (A) Compared to WT diaphragm, both mdx groups 
displayed a significant increase in fibrotic area (***p < 0.0001, n = 6). With treatment, 
fibrotic area was greatly reduced (**p = 0.0043, n = 6). (B) A similar pattern was 
observed in the hamstring, with a significant increase in fibrosis between WT and 
dystrophic muscle (WT vs. mdx ***p < 0.0001 and WT vs. treated mdx **p = 0.0046, n = 
6). Treated hamstring also contained considerably less fibrosis compared to the 
untreated (*p = 0.0279). (C) At 5 months, a significant increase in fibrotic area in 
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dystrophic muscle from WT was again found (WT vs. mdx *p = 0.0112 and WT vs. 
mdx+amIR *p = 0.0139, n = 6). Fibrosis decreased with treatment yet this was not 
statistically significant. (D) No distinct differences could be found between groups in the 
hamstring at 5 months. Bars represent mean with SEM. 
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Figure 3.8. Decreased hydroxyproline content with treatment. Hydroxyproline was 
quantified (A) diaphragm at 3 and 5 months and (B) hamstring at 3 months. (A) 
Hydroxyproline concentration was lower in WT diaphragm than either mdx group. All 
groups showed an increase in hydroxyproline from 3 to 5 months. While a small 
improvement was observed with treatment at 3 months, untreated mdx showed a much 
greater increase in hydroxyproline with time. (B) Hamstring muscle displayed a similar 
pattern, as dystrophic muscle contained higher levels of hydroxyproline, which was 
reduced with treatment. Bars represent mean with SEM.  
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Figure 3.9. Normalization of fiber diameter. Fiber diameter was measured at (A) 1 
month, (B) 3 months and (C) 5 months post-treatment. In WT muscle, a prominent peak 
at 60 μm across all timepoints. In contrast, the majority of dystrophic muscle fibers were 
small in size, with a peak at 10 μm. A slight shift toward normal sizes was observed with 
treatment, yet fibers were still smaller than WT overall. Bars represent mean. 
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Figure 3.10. Reduced fiber regeneration with treatment. Centronucleation was 
measured in diaphragm at (A) 3 months and (B) 5 months post-treatment. (A) 
Dystrophic muscle contained significantly more centrally nucleated fibers than the WT 
(WT vs. mdx and treated mdx ***p < 0.0001, n = 6 for all groups). A substantial 
decrease in centronucleation was found with treatment (mdx vs. mdx+amiR **p = 
0.0065, n = 6). (B) Similarly, a significant increase in the number of centrally nucleated 
fibers was found between WT and dystrophic muscle (WT vs. mdx ***p = 0.0003 and 
WT vs. mdx+amiR ***p < 0.0001, n = 6). Bars represent mean with SEM. 
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Figure 3.11. Improvements in overall muscle damage with treatment.  Serum CK 
levels were measured at (A) 3 months and (B) 5 months post-treatment. WT CK levels 
were consistently low, suggestive of minimal muscle damage at both timepoints. In 
contrast, mdx CK levels were generally much higher, with a considerable range 
amongst samples. (A) At 3 months post-treatment, treated mdx CK levels appeared to 
be lower, with less variation. (B) At 5 months, a similar pattern was observed in treated 
mice but there was less of a distinction between untreated mice. Points represent 
individual measurements, horizontal center bars represent means and vertical bars 
signify + SEM. 
  
  90 
 
 
 
 
 
Figure 3.12. Bodyweight in mdx mice. Bodyweight was measured in untreated and 
treated mdx mice, which steadily increased with time. No significant differences were 
observed with treatment.  
  
9
1
 
 
 
 
Figure 3.13. Muscle mass in mdx mice. Muscle mass was measured for different muscle groups at (A) 1 month, (B) 3 
months and (C) 5 months post-treatment. Treatment did not have a significant effect on mass for any muscle group. Bars 
represent mean with SEM. 
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Figure 3.14. Vector persistence in treated mdx mice. The number of viral genomes 
per cell were detected in (A) gastrocnemius and (B) diaphragm over time. (A) The 
number of vector genomes in gastrocnemius was maintained from 1 to 3 months, with a 
decrease at 5 months. (B) Viral genomes in the diaphragm were greatly reduced with 
time. Bars represent mean with SEM. 
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V. Discussion 
In this chapter, I examined the role of microRNA-206 in muscle pathology and if 
downregulation of miR-206 provides therapeutic benefit via expression of utrophin. First, 
I showed that administration of AAV9-anti-miR-206 significantly improved utrophin 
transcript levels in mdx mice and increased protein levels as well. Thus, downregulation 
of miR-206 diminishes its inhibitory effect on utrophin expression. After anti-miR-206 
treatment, muscle pathology in the mdx mice appeared to improve, with a normalization 
of muscle fiber morphology and organization and also a decrease in inflammatory cell 
infiltration. Lowered serum CK levels also reflected a reduction in overall muscle 
damage with treatment. A significant decrease in centronucleation signified 
improvements in muscle fiber stability, since regeneration occurs in response to active 
myofiber necrosis. A slight shift in myofiber size was observed with treatment; however, 
most fibers were still smaller and likely less mature than in the WT. Fiber size in the 
diaphragm showed a similar pattern (not shown). Coupled with the centronucleation 
results, it is possible that the treatment may prevent mature myofiber death, but has no 
effect on myoblast proliferation. Treatment also did not appear to affect body or muscle 
mass. 
Reducing microRNA-206 also appeared to influence a prominent aspect of the 
dystrophic phenotype, fibrosis. Masson trichrome staining revealed a significant 
decrease in collagen deposition. The presence of collagen fibers was examined by 
Picrosirius red/fast green staining, which showed that there were fewer mature fibers 
with treatment. Furthermore, increases in hydroxyproline content observed in the mdx 
diaphragm with time were stunted by treatment. These data suggest that 
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downregulation of miR-206 may delay progression of secondary disease pathways 
resulting from myofiber necrosis, such as fibrosis. 
While utrophin is a known therapeutic target and can prevent muscle damage 
and fibrosis associated with DMD pathology, it is important to note that any changes 
could be influenced by expression of additional miR-206 targets and through a variety of 
different mechanisms. As mentioned in Chapter II, increased VEGFA expression can 
improve muscle vascularization to better dystrophic pathology. IGF-1 is another 
therapeutic miR-206 target whose expression may be hampered as well (Engvall and 
Wewer 2003). It is possible that miR-206 downregulation depresses targets that work 
together to produce the improvements observed in this study. 
Nonetheless, there were obvious shortcomings with anti-miR-206 treatment. As 
discussed in Chapter II, miR-206 downregulation was short-lived and a marked 
reduction in viral genome was observed in the diaphragm. Interestingly, even though 
AAV transduction was initially lower in the hindlimb, motor function increases were still 
observed and may suggest that not all muscle fibers need to be transduced for 
therapeutic effect. Unlike utrophin gene replacement, sarcolemmal distribution in the 
majority of fibers was not observed. Studies suggest that only a two or three-fold 
increase is necessary to improve the dystrophic phenotype, so increased utrophin 
expression may only need occur in a fraction of fibers (Khurana and Davies 2003). 
Stronger staining in the neuromuscular junction with treatment also does not rule its 
contribution in improved function. In mdx; utrophin-/- mice, utrophin expression at the 
NMJ is greatly reduced and results in a decrease in the number of acetylcholine 
receptors by as much as 40%, suggesting that proper NMJ function is also affected in 
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DMD (Gramolini and Jasmin 1997). Furthermore, overexpression of PGC-1α, a 
transcriptional coactivator, enhanced NMJ function by improving motor neuron activity, 
resulting in improved muscle pathology and running performance in mdx mice 
(Handschin, Kobayashi et al. 2007). While dystrophic symptoms were greatly improved, 
miR-206 downregulation was not sufficient to completely alleviate pathology and 
prevent further muscle degeneration. Still, these data demonstrated that downregulation 
of miR-206 improve muscle pathology, supporting a deleterious role for miR-206 in 
DMD. In conclusion, this study draws attention to a previously unappreciated aspect of 
DMD and defines a new therapeutic avenue for muscular dystrophy. 
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CHAPTER 4: FUTURE DIRECTIONS 
I. Overall impact of the current study 
The goal of this study was to examine the role of microRNA-206 in mature 
muscle in secondary disease pathways that contribute to the dystrophic phenotype. The 
data presented here support a pathological role for miR-206, which is alleviated to some 
degree after miR-206 knockdown. This body of work also highlights the influence of 
secondary disease pathways on DMD pathology and their function in exacerbating the 
primary defect. Targeting dystrophin alone may not be sufficient to fully resolve 
symptoms and it is possible that concurrent disease mechanisms need to be addressed 
for complete recovery. 
Although treatment with AAV9-anti-miR-206 improved dystrophic symptoms, the 
effect is less striking compared to direct gene replacement therapies with mini- or micro-
dystrophin. Still, the lack of persistent gene expression and discovery of dystrophin-
targeted T cell responses observed in DMD patients have halted progression of such 
therapies, spurring investigation into alternative AAV serotypes and strategies for 
increasing efficacy (Kornegay, Li et al. 2010, Mendell , Campbell  et al. 2010). DMD 
patients may develop an immune response to the therapeutic dystrophin gene or to 
dystrophin expressed by revertant fibers. Therefore, strategies that seek to increase 
endogenous expression of booster genes may fare better. One example is treatment 
with an utrophin upregulator, which works by increasing expression of endogenous 
utrophin and has shown promise in clinical trials (Tinsley, Fairclough et al. 2011). 
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A major obstacle in DMD treatments is the size limit of presently available 
vectors. The full-length dystrophin gene is 2.4 Mbp with a cDNA length of 14 kb. Current 
gene therapy strategies rely on producing a truncated dystrophin protein to produce a 
milder phenotype similar to Becker muscular dystrophy. Using short sequences to affect 
microRNA-mediated regulation are more amenable to size constraints and are more 
versatile through their ability to target multiple pathways. Here, I have shown for the first 
time that using AAV-mediated microRNA downregulation has therapeutic potential for 
DMD, supporting further exploration into aberrant microRNA expression in other 
diseases that may benefit from a similar approach. 
II. Possible future studies 
MicroRNA-206 is known to be upregulated in both mdx mice and DMD patients, 
suggesting that this therapy could eventually be translated to human use (Greco, De 
Simone et al. 2009). Additional investigation to quantify miR-206 and miR-206 target 
expression in humans is needed to determine if patients would benefit from this therapy. 
Verification of miR-206 target binding in humans is also necessary. While miR-206 is 
upregulated in humans, it is possible that the amount of miR-206 or anti-miR-206 
binding is not similar to mice, which would affect therapeutic efficacy of this treatment. 
Adjustments could be made to the anti-miR-206 sequence to increase miR-206 
sequestration in humans. 
The full potential of this therapy may also be obscured by insufficient depletion of 
miR-206. Although no attempt was made during this study to maximize microRNA 
binding efficacy, another group showed that up to 7 binding sites for another microRNA 
can be placed on a decoy target, after which the knockdown effect was saturated 
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(Haraguchi, Ozaki et al. 2009). This warrants further exploration into dosing and 
additional miR-206 binding sites on the decoy target. 
Presently available AAV vectors also do not efficiently transduce satellite, or 
muscle precursor, cells, which highly express miR-206 (Arnett, Konieczny et al. 2014). 
This may be an advantage, since one major concern of targeting the satellite cells 
would be interference with normal muscle maturation. However, it has been 
hypothesized that muscle precursors are unable to differentiate due to inhibitory factors 
in the diseased microenvironment (Oexle and Kohlschütter 2001). Since miR-206 levels 
decrease as muscle cells mature, it would be interesting to see if miR-206 reduction 
would affect differentiation or aid in repopulating the muscle with differentiated fibers. 
While miR-206 is known to inhibit transcription factor Pax7 expression during early 
stages of differentiation, it is unclear what role miR-206 plays at later timepoints. Further 
study into the expression profile of miR-206 over time and whether this pattern is 
perturbed in DMD would be very useful for understanding the best way to utilize this 
therapy. 
III. Considerations for DMD therapies 
 While we now have a better understanding of miR-206 function in DMD, the 
current results indicate that miR-206 reduction would not have an immediate impact on 
functional deficits. Because this treatment affects secondary disease mechanisms and 
does not appear to increase sarcolemmal utrophin expression globally, it can only work 
to lessen the severity of pathology and cannot prevent membrane instability and 
eventual muscle death. As mentioned previously, improvements to the current 
therapeutic design could be made. However, anti-miR-206 treatment may be useful in 
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combination with gene therapies that increase dystrophin levels. For example, AAVs 
carrying mini-dystrophin and anti-miR-206 could be co-delivered to target both primary 
and secondary disease mechanisms. Direct administration of an oligonucleotide with 
the anti-miR-206 sequence, similar to AONs for exon skipping therapies, could also 
easily be incorporated into existing therapies and allow for changes in dosing or even 
repeated dosing. 
IV. Conclusions 
Although additional verification is needed for eventual clinical application of anti-
miR-206 treatment, I have shown for the first time that miR-206 can be targeted to elicit 
a therapeutic effect. I also show that miR-206 affects beneficial gene expression, 
supporting its pathological role. In summary, I have uncovered evidence for a previously 
unappreciated disease mechanism as well as a novel therapeutic paradigm for 
Duchenne muscular dystrophy, bringing us another step closer to a cure.
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